

OVERVIEW

OVERVIEW <u>HIGHLIGHTS</u>


- Lung And Bronchus was the leading type of cancer for incidence, inpatient hospital discharges and mortality in Nevada from 2000 to 2004. This type of cancer accounted for 15.7% of the total cancer incidence, 13.9% of all cancer inpatient hospital discharges, and 31.0% of cancer mortality during this period.
- Thyroid Gland Cancer by far had the highest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 34.99, from 2000 to 2004. This means that for every 100 deaths from Thyroid Gland Cancer there would be 3,499 cases. The second leading type was Hodgkin's Lymphoma with a ratio of 7.08.
- Pancreatic Cancer had the lowest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 1.04 during this period. This means that for every 100 deaths from Pancreatic Cancer there were 104 cases. The second leading type of cancer, Liver and Intrahepatic Bile Ducts, had a ratio of 1.08.







Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the respective data source.

Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 2000-2004







| | Incide | nce | Inpatient Di | Mort | |
|--|--------|--------|--------------|--------|--------|
| Type of Cancer | Number | Rate* | Number | Rate* | Number |
| Total | 49,963 | 480.00 | 34,796 | 330.00 | 19,379 |
| Lip, Oral Cavity and Pharynx | 1,171 | 11.00 | 526 | 4.80 | 296 |
| Lip | 48 | 0.46 | 8 | | 2 |
| Base of Tongue | 184 | 1.70 | 90 | 0.81 | 3 |
| Other & Unspecified Parts of Tongue | 182 | 1.70 | 95 | 0.86 | 77 |
| Parotid Gland | 96 | 0.96 | 46 | 0.44 | 15 |
| Other & Unspecified Major Salivary glands | 30 | 0.28 | 10 | 0.08 | 3 |
| Floor of Mouth | 89 | 0.83 | 46 | 0.40 | 3 |
| Gum | 33 | 0.31 | 31 | 0.29 | 4 |
| Palate | 47 | 0.45 | 12 | 0.11 | 6 |
| Other & Unspecified Parts of Mouth | 61 | 0.58 | 26 | 0.24 | 26 |
| Nasopharynx | 70 | 0.64 | 24 | 0.21 | 28 |
| Tonsil | 162 | 1.50 | 43 | 0.38 | 19 |
| Oropharynx | 48 | 0.43 | 24 | 0.21 | 20 |
| Pyriform Sinus | 45 | 0.44 | 16 | 0.15 | 1 |
| Hypopharynx | 41 | 0.37 | 25 | 0.22 | 3 |
| Other & Unspecified Oral (Buccal) Cavity & Pharynx | 35 | 0.33 | 30 | 0.30 | 86 |
| Digestive System | 8,452 | 84.00 | 7,018 | 69.00 | 4,527 |
| Esophagus | 545 | 5.20 | 302 | 2.90 | 459 |
| Stomach | 639 | 6.40 | 597 | 5.80 | 346 |
| Small Intestine | 140 | 1.30 | 161 | 1.60 | 34 |
| Colon (excluding Rectum) | 3,593 | 36.00 | 2,966 | 30.00 | 1,718 |
| Cecum | 827 | 8.50 | 643 | 6.70 | 10 |
| Appendix | 50 | 0.49 | 34 | 0.31 | 4 |
| Ascending Colon | 543 | 5.60 | 553 | 5.60 | 3 |
| Hepatic Flexure | 147 | 1.50 | 126 | 1.30 | 0 |
| Transverse Colon | 263 | 2.70 | 258 | 2.70 | 1 |
| Splenic Flexure | 97 | 0.91 | 111 | 1.10 | 0 |
| Descending Colon | 182 | 1.80 | 151 | 1.50 | 0 |
| Sigmoid Colon | 1,038 | 10.00 | 789 | 7.70 | 10 |
| Large Intestine, NOS | 446 | 4.70 | 301 | 3.00 | 1,690 |
| Rectum | 959 | 9.20 | 726 | 7.00 | 205 |
| Rectosigmoid Junction | 474 | 4.60 | 598 | 5.70 | 86 |
| Anus, Anal Canal and Anorectum | 147 | 1.40 | 143 | 1.40 | 21 |
| Liver | 503 | 4.80 | 336 | 3.20 | 419 |
| Intrahepatic Bile Ducts | 52 | 0.53 | 43 | 0.43 | 82 |
| Gallbladder | 68 | 0.68 | 29 | 0.28 | 39 |
| Other & Unspecified Biliary Tract | 160 | 1.60 | 151 | 1.50 | 51 |
| Pancreas | 1,075 | 11.00 | 848 | 8.30 | 1,017 |
| Retroperitoneum | 42 | 0.38 | 55 | 0.51 | 4 |
| Peritoneum, Omentum and Mesentery | 34 | 0.32 | 54 | 0.50 | 15 |
| Other Digestive Organs | 21 | 0.20 | 9 | | 31 |
| Respiratory System | 8,401 | 81.00 | 5,155 | 49.00 | 6,138 |
| Nasal Cavity and Middle Ear | 40 | 0.38 | 10 | -0.00 | 0,100 |
| Accessory Sinuses | 33 | 0.30 | 10 | 0.11 | 13 |
| Larynx | 391 | 3.70 | 166 | 1.60 | 108 |
| Lung and Bronchus | 7,839 | 76.00 | 4,842 | 46.00 | 6,005 |

Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality byType of Cancer, Nevada, 2000-2004

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and ageadjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality byType of Cancer, Nevada, 2000-2004 (Continued)

| Time (10 | Incide | Incidence | | scharges | Mortality | |
|---|--------|-----------|--------|----------|-----------|--------|
| Type of Cancer | Number | Rate* | Number | Rate* | Number | Rate* |
| Total | 49,963 | 480.00 | 34,796 | 330.00 | 19,379 | 197.00 |
| Skin (Excluding Basal And Squamous) | 2,023 | 19.00 | 206 | 2.00 | 378 | 3.70 |
| Melanomas Of The Skin | 2,023 | 19.00 | 93 | 0.86 | 298 | 2.80 |
| Other Non-Epithelial Skin | 0 | | 113 | 1.10 | 80 | 0.83 |
| Breast | 7,824 | 73.00 | 2,276 | 22.00 | 1,357 | 14.00 |
| Female Genital System* | 2,474 | 45.00 | 2,488 | 45.00 | 801 | 15.00 |
| Cervix Uteri* | 514 | 9.40 | 609 | 11.00 | 149 | 2.80 |
| Corpus Uteri* | 986 | 18.00 | 915 | 17.00 | 59 | 1.10 |
| Uterus, NOS* | 47 | 0.88 | 31 | 0.58 | 96 | 1.90 |
| Ovary* | 734 | 13.00 | 721 | 13.00 | 456 | 8.50 |
| Vagina* | 33 | 0.62 | 37 | 0.70 | 10 | 0.19 |
| Vulva* | 132 | 2.50 | 129 | 2.40 | 18 | 0.35 |
| Placenta* | 4 | | 3 | | 0 | |
| Other Female Genital Organs* | 24 | 0.44 | 43 | 0.77 | 13 | 0.26 |
| Male Genital System* | 7,880 | 158.00 | 2,682 | 51.00 | 1,016 | 28.00 |
| Prostate* | 7,569 | 153.00 | 2,614 | 50.00 | 995 | 27.00 |
| Testis* | 268 | 4.70 | 51 | 0.87 | 15 | 0.30 |
| Penis* | 27 | 0.62 | 15 | 0.37 | 4 | |
| Other Male Genital Organs* | 16 | 0.32 | 2 | | 2 | |
| Urinary System | 3,978 | 39.00 | 2,191 | 21.00 | 902 | 9.30 |
| Urinary Bladder | 2,567 | 26.00 | 1,033 | 11.00 | 474 | 5.10 |
| Kidney | 1,237 | 12.00 | 986 | 9.10 | 396 | 3.90 |
| Renal Pelvis | 73 | 0.70 | 84 | 0.82 | 4 | |
| Ureter | 56 | 0.54 | 71 | 0.70 | 11 | 0.10 |
| Other Urinary Organs | 45 | 0.47 | 17 | 0.16 | 17 | 0.17 |
| Eye and Orbit | 63 | 0.61 | 9 | | 8 | |
| Brain and Other Central Nervous System | 663 | 6.30 | 946 | 8.80 | 415 | 4.00 |
| Brain | 611 | 5.80 | 874 | 8.10 | 409 | 3.90 |
| Meninges | 25 | 0.24 | 47 | 0.44 | 2 | |
| Spinal Cord, Cranial Nerves, & Other Parts of CNS | 27 | 0.25 | 25 | 0.23 | 4 | |
| Endocrine System | 1,178 | 11.00 | 1,617 | 15.00 | 53 | 0.53 |
| Thyroid Gland | 1,126 | 10.00 | 1,570 | 14.00 | 29 | 0.29 |
| Adrenal Gland | 19 | 0.19 | 19 | 0.18 | 14 | 0.14 |
| Other Endocrine (Including Thymus) | 33 | 0.32 | 28 | 0.28 | 10 | 0.10 |
| Hodgkin's Lymphoma | 279 | 2.50 | 118 | 1.10 | 37 | 0.35 |
| Non-Hodgkin's Lymphoma | 1,815 | 18.00 | 1,055 | 10.00 | 630 | 6.60 |
| Multiple Myeloma | 453 | 4.40 | 373 | 3.60 | 341 | 3.40 |
| Leukemia | 1,201 | 12.00 | 1,041 | 10.00 | 699 | 7.30 |
| Lymphocytic | 553 | 5.40 | 442 | 4.20 | 184 | 2.00 |
| Acute Lymphocytic | 137 | 1.30 | 302 | 2.80 | 44 | 0.44 |
| Chronic Lymphocytic | 381 | 3.80 | 136 | 1.40 | 128 | 1.40 |
| Other Lymphocytic | 35 | 0.33 | 4 | | 12 | 0.13 |
| Myeloid and Monocytic | 565 | 5.60 | 552 | 5.30 | 295 | 3.00 |
| Acute Myeloid | 396 | 3.90 | 443 | 4.30 | 227 | 2.30 |
| Acute Monocytic | 22 | 0.24 | 10 | 0.11 | 2 | |
| Chronic Myeloid | 133 | 1.30 | 92 | 0.92 | 47 | 0.47 |
| Other Myeloid/Monocytic | 14 | 0.14 | 7 | | 19 | 0.20 |
| Other | 83 | 0.91 | 47 | 0.47 | 220 | 2.30 |
| Other Acute | 39 | 0.40 | 33 | 0.33 | 84 | 0.84 |
| Aleukemic, Subleukemic and NOS | 44 | 0.51 | 14 | 0.14 | 136 | 1.50 |
| Mesothelioma | 0 | | 1 | | 73 | 0.72 |
| Kaposi Sarcoma | 0 | | 0 | | 0 | |
| Other, III-Defined and Unspecified Sites | 1,763 | 18.00 | 6,798 | 64.00 | 1,535 | 16.00 |

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient HospitalDischarges and Mortality, Nevada Residents, 2000-2004

| Type of Cancer | Incidence | | Hosp Admis | | Mortality | | |
|--|-----------|---------|---------------|---------|-----------|---------|--|
| | Number | Percent | Number | Percent | Number | Percent | |
| Lung and Bronchus | 7,838 | 15.7% | 4,842 | 13.9% | 6,005 | 31.0% | |
| Breast | 7,823 | 15.7% | 2,276 | 6.5% | 1,357 | 7.0% | |
| Prostate | 7,569 | 15.2% | 2,614 | 7.5% | 995 | 5.1% | |
| Lip, Oral Cavity and Pharynx | 1,171 | 2.3% | 526 | 1.5% | 296 | 1.5% | |
| Urinary Bladder | 2,567 | 5.1% | 1,033 | 3.0% | 474 | 2.4% | |
| Non-Hodgkin's Lymphoma | 1,815 | 3.6% | 1,055 | 3.0% | 630 | 3.3% | |
| Pancreas | 1,074 | 2.1% | 848 | 2.4% | 1,017 | 5.2% | |
| Thyroid Gland | 1,126 | 2.3% | 1,570 | 4.5% | 29 | 0.1% | |
| Ovary | 734 | 1.5% | 721 | 2.1% | 457 | 2.4% | |
| Stomach | 639 | 1.3% | 597 | 1.7% | 346 | 1.8% | |
| Esophagus | 545 | 1.1% | 302 | 0.9% | 459 | 2.4% | |
| Cervix Uteri | 514 | 1.0% | 609 | 1.8% | 149 | 0.8% | |
| Multiple Myeloma | 453 | 0.9% | 373 | 1.1% | 341 | 1.8% | |
| Larynx | 391 | 0.8% | 166 | 0.5% | 108 | 0.6% | |
| Hodgkin's Lymphoma | 279 | 0.6% | 117 | 0.3% | 37 | 0.2% | |
| Colorectal | 5,173 | 10.4% | 4,433 | 12.7% | 2,030 | 10.5% | |
| Kidney and Renal Pelvis | 1,310 | 2.6% | 1,070 | 3.1% | 400 | 2.1% | |
| Leukemia | 1,200 | 2.4% | 1,040 | 3.0% | 699 | 3.6% | |
| Skin | 2,022 | 4.0% | 93 | 0.3% | 298 | 1.5% | |
| Corpus Uteri & Uterus NOS | 1,033 | 2.1% | 946 | 2.7% | 156 | 0.8% | |
| Brain and Other Central Nervous System | 663 | 1.3% | 946 | 2.7% | 415 | 2.1% | |
| Liver and Intrahepatic Bile Ducts | 555 | 1.1% | 379 | 1.1% | 501 | 2.6% | |
| All Other Sites | 3,463 | 6.9% | 8,237 | 23.7% | 2,180 | 11.2% | |
| Total | 49,957 | 100.0% | 34,793 | 100.0% | 19,379 | 100.0% | |

Note: Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please See Technical Notes for more information.

REPORT ON CANCER IN NEVADA 2000-2004

Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality,Nevada Residents, 2000-2004

Total

| 1 Lung And Bronchus 7,838 15.7% Lung And Bronchus 4,433 12.7% Colorectal 2 Breast 7,823 15.7% Colorectal 4,433 12.7% Colorectal 3 Prostate 7,569 Breast 2,276 6.5% Pancest 4 Colorectal 5.173 10.4% Breast 2,276 6.5% Pancest 5 Urinary Bladder 2,567 5.1% Thyroid Gland 1,570 4.5% Prostate 6 Skin 2,022 4.0% Kidney And Renal Pelvis 1,000 3.0% Lung And Bronchus 9 Leukernia 1,040 3.0% Lure And Intrahepatic Bile Duct: 3.0% Unrany Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus Total 49,963 100.0% Total 34,796 100.0% Total 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Li | Mortolity | | | |
|--|-----------|---------|--|--|
| 1 Lung And Bronchus 7,838 15,7% Lung And Bronchus 4,433 12,7% Colorectal 2 Breast 7,823 15,7% Colorectal 4,433 12,7% Colorectal 3 Prostate 7,569 Breast 2,276 6,5% Pancreas 4 Colorectal 5,1% Frootate 2,276 6,5% Pancreas 5 Urinary Bladder 2,567 5.1% Thyroid Gland 1,570 4,5% Prostate 6 Skin 2,022 4,0% Kidney And Renal Pelvis 1,040 3,0% Uriner And Intrahepatic Bile Ducts 9 Leukernia 1,040 3,0% Uriner Magkins Lymphoma 1,055 3,0% Uriner Magkins Lymphoma 10 Lip, Oral Cavity And Pharynx 1,171 2,3% Corpus Uteri & Uterus Nos 946 2,7% Esophagus 10 Lip, Oral Cavity And Pharynx 1,171 2,3% Total 34,796 100.0% Total 10 Prostate 7,569 </td <td></td> <td></td> | | | | |
| 2 Breast 7.823 15.7% Colorectal 4.433 12.7% Colorectal 3 Prostate 7.669 15.1% Prostate 2.614 7.5% Breast 4 Colorectal 5.13% Thyrind Gland 1.670 4.5% Prostate 5 Urinary Bladder 2.567 5.1% Thyrind Gland 1.670 3.0% Leukernia 7 Non-Hodgkins Lymphoma 1.815 3.6% Non-Hodgkins Lymphoma 1.055 3.0% Uner And Intrahepatic Bile Ducts 9 Leukernia 1.000 2.4% Urinary Bladder 1.033 3.0% Unrer And Intrahepatic Bile Ducts 9 Leukernia 1.010 38.488 77.0% Total of Top 10 20.879 60.0% Total of Top 10 7.580 15.1% 10 Lip, Oral Castly And Pharynx 1.171 2.3% Corpostate 2.07% Esophagus Total of Top 10 20.879 60.0% Total of Top 10 10.0% Total 10 Prostate | Number | Percent | | |
| 3 Prostate 7.569 15.1% Prostate 2,276 6.5% Breast 4 Colorectal 5.173 10.4% Breast 2,227 6.5% Prostate 5 Urinary Bladder 2,267 5.1% Thyroid Gland 1,570 4.5% Prostate 6 Skin 2,222 4.0% Kidney And Renal Pelvis 1,010 3.1% Leukemia 1,040 3.0% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 1,310 2.6% Leukemia 1,040 3.0% Kinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 11 Lor of Top 10 38,488 77.0% Total of Top 10 2.9,470 Total of Top 10 Top 10 12 Long And Bronchus 4,139 8.3% Long And Bronchus 7,1% | 6,005 | 31.0% | | |
| 4 Colorectal 5, 173 10.4% Breast 2, 276 6.5% Pancreas 5 Winary Bladder 2, 577 5.1% Thynoid Gland 1, 570 3.1% Leukemia 6 Skin 2, 022 4.0% Kidney And Renal Pelvis 1, 010 3.1% Leukemia 7 Non-Hodgkins Lymphoma 1, 815 3.6% Non-Hodgkins Lymphoma 1, 055 3.0% Non-Hodgkins Lymphoma 9 Leukemia 1, 200 2.6% Leukemia 1, 040 3.0% Uriary Bladder 1, 033 3.0% Uniary Bladder 9 Leukemia 1, 200 2.4% Urinary Bladder 1, 033 3.0% Uniary Bladder 10 Lip, Oral Cavity And Pharynx 1, 171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 10 Lotal of Top 10 38.4% 7.6% Total of Top 10 20.879 60.0% Total 11 Prostate 7.669 15.1% Prostate 2,643 7.1% Colorectal 12 Lung And Bronchus 4,139 8.3% | 2,030 | 10.5% | | |
| 5Urinary Bladder2,6675,1%Thyroid Gland1,5704,5%Prostate6Skin2,0224.0%Kidney And Renal Pelvis1,0703,1%Leukemia7Non-Hodgkins Lymphoma1,8153.6%Non-Hodgkins Lymphoma1,0653,0%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis1,3102.6%Urinary Bladder1,0333,0%Urinary Bladder10Leukemia1,2002.4%Urinary Bladder1,0333,0%Urinary Bladder10Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48877.0%Total of Top 1020,87960.0%Total of Top 10-Total of Top 1038,48810.0%Total of Top 107.5%Long And Bronchus1,6761Prostate7.5%Ising Parceas7.5%Long And Bronchus2,4637.1%Long And Bronchus3Colorectal2,8105.6%Colorectal2,3006.6%Prostate4Urinary Bladder1,9814.0%Urinary Bladder5831.7%Long And Bronchus5241.5%4Urinary Bladder1,0255.5%Kidney And Renal Pelvis541< | 1,357 | 7.0% | | |
| 6 Skin 2.022 4.0% Kidney And Renal Pelvis 1.070 3.1% Leukemia 7 Non-Hodgkins Lymphoma 1.815 3.6% Non-Hodgkins Lymphoma 1.055 3.0% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 1.310 2.6% Leukemia 1.040 3.0% Liver And Intrahepatic Bile Ducts 9 Leukemia 1.200 2.4% Urnary Bladder 1.033 3.0% Liver And Intrahepatic Bile Ducts 10 Lip, Oral Cavity And Pharynx 1.171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus - Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 - Total 49,963 100.0% Total 34.796 100.0% Total of Top 10 1 Prostate 7.1% Lung And Bronchus 2.463 7.1% Colorectal 2 Lung And Bronchus 4.139 8.3% Lung And Bronchus 2.464 7.1% Colorectal | 1,017 | 5.2% | | |
| 7 Non-Hodgkins Lymphoma 1,815 3.6% Non-Hodgkins Lymphoma 1,055 3.0% Non-Hodgkins Ligmphoma 8 Kidney And Renal Pelvis 1,200 2.4% Leukemia 1,003 3.0% Liver And Intrahepatic Bile Ducts 9 Leukemia 1,200 2.4% Urinary Bladder 1,033 3.0% Urinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus 7 Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 7 Total 49,963 100.0% Total 34,796 100.0% Total 7 Total 49,963 100.0% Total 7.5% Lung And Bronchus 2,843 1 Prostate 7.569 15.1% Prostate 2,643 7.5% Lung And Bronchus 2 Colorectal 2,840 5.6% Colorectal 2,300 6.6% Prostate 6.6% Prostate | 995 | 5.1% | | |
| 8 Kidney And Renal Pelvis 1,310 2.6% Leukemia 1,040 3.0% Liver And Intrahepatic Bile Ducts 9 Leukemia 1,200 2.4% Urinary Bladder 1,033 3.0% Urinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uleria & Ulerus Nos 94 2.7% Esophagus 7010 10 38.488 77.0% Total of Top 10 20.879 60.0% Total of Top 10 - Total 49.963 100.0% Total 34,796 100.0% Total 7 Total 10.1dence Hospital Admissions Mortality Mortality 7 Upg And Bronchus 4,139 8.3% Lung And Bronchus 2,430 6.6% Prostate 2.3% Pancreas 3 Colorectal 2,810 5.6% Colorectal 2.3% Pancreas 1.7% Sophagus 4 Urinary Bladder 1,981 4.0% Urinary Bladder 8.3% 1.7% Sophagus 1.7%< | 699 | 3.6% | | |
| 9 Leukomia 1.200 2.4% Urinary Bladder 1,033 3.0% Urinary Bladder 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos 946 2.7% Esophagus Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 Total of Top 10 20,879 60.0% Total 34,796 100.0% Total Male Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 3 Colorectal 2,310 5.6% Kicholy And Renal Pelvis 664 2.0% Leukemia | 630 | 3.3% | | |
| 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos. 946 2.7% Esophagus Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 - Total 49,963 100.0% Total 34,796 100.0% Total Male Male Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,463 7.1% Colorectal 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2.300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia <t< td=""><td>501</td><td>2.6%</td></t<> | 501 | 2.6% | | |
| 10 Lip, Oral Cavity And Pharynx 1,171 2.3% Corpus Uteri & Uterus Nos. 946 2.7% Esophagus Total of Top 10 38,488 77.0% Total of Top 10 20,879 60.0% Total of Top 10 - Total 49,963 100.0% Total 34,796 100.0% Total Male Male Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,463 7.1% Colorectal 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2.300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia <t< td=""><td>474</td><td>2.4%</td></t<> | 474 | 2.4% | | |
| - Total 49,963 100.0% Total 34,796 100.0% Total Male Incidence Hospital Admissions Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 2,483 7.1% Colorectal 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 597 1.7% Non-Hodgkins Lymphoma 1035 2.1% Lukemia 583 1.7% Non-Hodgkins Lymphoma 1035 2.1% Lukemia 1.5% Liver And Intrahepatic Bile Ducts | 459 | 2.4% | | |
| Male Hospital Admissions Mortality Type Number Percent Hospital Admissions Mortality 1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal Colorectal 2,300 6.6% Prostate Colorectal Prostate 1.014nary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 597 1.7% Isophagus Leukemia 597 1.7% Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 1.035 2.1% Leukemia 597 1.7% Non-Hodgkins Lymphoma 1.035 2.1% Non-Hodgkins Lymphoma 1.0% Non-Hodgkins Lymphoma Liver And Intrahepatic Bile Ducts 1.0% | 14,167 | 73.1% | | |
| Ranking Incidence Hospital Admissions Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,669 15.1% Prostate 2,614 7.5% Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 10 Pancreas 552 1.1% Stomach 409 1.2% <td< td=""><td>19,379</td><td>100.0%</td></td<> | 19,379 | 100.0% | | |
| Ranking Incidence Hospital Admissions Mortality Type Number Percent Type Number Percent Type 1 Prostate 7,669 15.1% Prostate 2,614 7.5% Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 2,300 6.6% Prostate 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 10 Pancreas 552 1.1% Stomach 409 1.2% <td< th=""><th></th><th></th></td<> | | | | |
| TypeNumberPercentTypeNumberPercentType1Prostate7,56915.1%Prostate2,6147.5%Lung And Bronchus2Lung And Bronchus4,1398.3%Lung And Bronchus2,4637.1%Colorectal3Colorectal2,8105.6%Colorectal2,3006.6%Prostate4Urinary Bladder1,9814.0%Urinary Bladder8032.3%Pancreas5Skin1,2272.5%Kidney And Renal Pelvis6942.0%Leukemia6Non-Hodgkins Lymphoma1,0352.1%Leukemia5971.7%Resolvagus7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Kidney And Renal Pelvis10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis10Evelkemia26,366100.0%Total16,799100.0%Total1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1% | | | | |
| 1 Prostate 7,569 15.1% Prostate 2,614 7.5% Lung And Bronchus 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Brain And Other Central Nervous 524 1.5% Live And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Urinary Bladder 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis Total of Top 10 | Number | Percent | | |
| 2 Lung And Bronchus 4,139 8.3% Lung And Bronchus 2,463 7.1% Colorectal 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervour 524 1.5% Lure And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Kidney And Renal Pelvis 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis | | 16.7% | | |
| 3 Colorectal 2,810 5.6% Colorectal 2,300 6.6% Prostate 4 Urinary Bladder 1,981 4.0% Urinary Bladder 803 2.3% Pancreas 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervou: 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Brain And Other Central Nervou: 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Brain And Other Central Nervou: 524 1.5% Liver And Renal Pelvis 10 Pancreas 552 1.1% Stomach 409 1.2% Kid | 3,244 | | | |
| 4Urinary Bladder1,9814.0%Urinary Bladder8032.3%Pancreas5Skin1,2272.5%Kidney And Renal Pelvis6942.0%Leukemia6Non-Hodgkins Lymphoma1,0352.1%Leukemia5971.7%Esophagus7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis7Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-IncidenceHospital AdmissionsMortalityMortalityMortality2 | 1,120 | 5.8% | | |
| 5 Skin 1,227 2.5% Kidney And Renal Pelvis 694 2.0% Leukemia 6 Non-Hodgkins Lymphoma 1,035 2.1% Leukemia 597 1.7% Esophagus 7 Lip, Oral Cavity And Pharynx 846 1.7% Non-Hodgkins Lymphoma 583 1.7% Non-Hodgkins Lymphoma 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervous 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Urinary Bladder 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis 6 100 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total 26,366 100.0% Total 16, | 995 | 5.1% | | |
| 6Non-Hodgkins Lymphoma1,0352.1%Leukemia5971.7%Esophagus7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis10rotal of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%Total-Total7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas | 529 | 2.7% | | |
| 7Lip, Oral Cavity And Pharynx8461.7%Non-Hodgkins Lymphoma5831.7%Non-Hodgkins Lymphoma8Kidney And Renal Pelvis8431.7%Brain And Other Central Nervous5241.5%Liver And Intrahepatic Bile Ducts9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal Pelvis10Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-Total26,366100.0%Total16,799100.0%Total-IncidenceHospital AdmissionsMortality-TypeNumberPercentTypeMortality-1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%BreastColorectal3Colorectal2,3634.7%Corpus Uter | 421 | 2.2% | | |
| 8 Kidney And Renal Pelvis 843 1.7% Brain And Other Central Nervous 524 1.5% Liver And Intrahepatic Bile Ducts 9 Leukemia 700 1.4% Pancreas 418 1.2% Urinary Bladder 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis 10 Pancreas 552 1.1% Stomach 409 1.2% Kidney And Renal Pelvis 10 Pancreas 552 1.1% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 11,405 67.9% Total of Top 10 - Total of Top 10 21,702 82.3% Total of Top 10 10.0% Total - Total of Top 10 21,702 82.3% Total of Top 10 Total of Top 10 - Total 26,366 100.0% Total 16,799 100.0% Total | 368 | 1.9% | | |
| 9Leukemia7001.4%Pancreas4181.2%Urinary Bladder10Pancreas5521.1%Stomach4091.2%Kidney And Renal PelvisTotal of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%TotalFemaleRankingIncidenceFemaleRankingIncidenceType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | 357 | 1.8% | | |
| 10Pancreas5521.1%Stomach4091.2%Kidney And Renal PelvisTotal of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%TotalFemaleRankingIncidenceMortality1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | 348 | 1.8% | | |
| Total of Top 1021,70282.3%Total of Top 1011,40567.9%Total of Top 10-Total26,366100.0%Total16,799100.0%TotalFemaleRankingIncidenceMumberPercentMortalityIncidencePercentMortality1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | 339 | 1.7% | | |
| Female Mortality Ranking Incidence Hospital Admissions Mortality 1 Breast 7,742 15.5% Lung And Bronchus 2,379 6.8% Lung And Bronchus 2 Lung And Bronchus 3,699 7.4% Breast 2,253 6.5% Breast 3 Colorectal 2,363 4.7% Colorectal 2,133 6.1% Colorectal 4 Corpus Uteri & Uterus Nos 1,033 2.1% Thyroid Gland 1,238 3.6% Pancreas 5 Thyroid Gland 881 1.8% Corpus Uteri & Uterus Nos 946 2.7% Ovary | 265 | 1.4% | | |
| Female Mortality Mortality Type Number Percent Mortality 1 Breast 7,742 15.5% Lung And Bronchus 2,379 6.8% Lung And Bronchus 2 Lung And Bronchus 3,699 7.4% Breast 2,253 6.5% Breast 3 Colorectal 2,363 4.7% Colorectal 2,133 6.1% Colorectal 4 Corpus Uteri & Uterus Nos 1,033 2.1% Thyroid Gland 1,238 3.6% Pancreas 5 Thyroid Gland 881 1.8% Corpus Uteri & Uterus Nos 946 2.7% Ovary | 7,986 | 76.8% | | |
| RankingIncidenceMortalityTypeNumberPercentTypeNumberPercentType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | 10,396 | 100.0% | | |
| RankingIncidenceHospital AdmissionsMortalityTypeNumberPercentTypeNumberPercentType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | | | | |
| TypeNumberPercentTypeNumberPercentType1Breast7,74215.5%Lung And Bronchus2,3796.8%Lung And Bronchus2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | | | | |
| 2Lung And Bronchus3,6997.4%Breast2,2536.5%Breast3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | Number | Percent | | |
| 3Colorectal2,3634.7%Colorectal2,1336.1%Colorectal4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | 2,761 | 14.2% | | |
| 4Corpus Uteri & Uterus Nos1,0332.1%Thyroid Gland1,2383.6%Pancreas5Thyroid Gland8811.8%Corpus Uteri & Uterus Nos9462.7%Ovary | 1,342 | 6.9% | | |
| 5 Thyroid Gland 881 1.8% Corpus Uteri & Uterus Nos 946 2.7% Ovary | 910 | 4.7% | | |
| | 488 | 2.5% | | |
| | 456 | 2.4% | | |
| 6 Skin 795 1.6% Ovary 721 2.1% Leukemia | 278 | 1.4% | | |
| 7 Non-Hodgkins Lymphoma 780 1.6% Cervix Uteri 609 1.8% Non-Hodgkins Lymphoma | 273 | 1.4% | | |
| 8 Ovary 734 1.5% Non-Hodgkins Lymphoma 472 1.4% Brain And Other Central Nervous | 175 | 0.9% | | |
| 9 Urinary Bladder 586 1.2% Leukemia 443 1.3% Corpus Uteri & Uterus Nos | 155 | 0.8% | | |
| 10 Pancreas 522 1.0% Pancreas 430 1.2% Liver And Intrahepatic Bile Ducts | 153 | 0.8% | | |
| Total of Top 10 19,135 81.1% Total of Top 10 11,624 64.6% Total of Top 10 | 6,991 | 77.8% | | |
| - Total 23,591 100.0% Total 17,994 100.0% Total | 8,983 | 100.0% | | |
| Note: Those of other/unknown gender are not listed separately, but are included in the total. | | | | |


Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the LeadingTypes of Cancer, Nevada Residents, 2000-2004


| T | | Incidence | e | | 1 | Ratio | |
|--|--------|-----------|---------------|--------|-------|---------------|-------|
| Type of Cancer | Number | Rate* | 95% C.I. | Number | Rate* | 95% C.I. | Ratio |
| Lung and Bronchus | 7,839 | 75.77 | (74.1-77.5) | 6,005 | 59.26 | (57.7-60.8) | 1.28 |
| Breast* | 7,742 | 140.8 | (137.7-144.0) | 1,342 | 25.2 | (23.9-26.6) | 5.59 |
| Prostate* | 7,569 | 152.8 | (149.3-156.5) | 995 | 27.4 | (25.6-29.4) | 5.57 |
| Colorectal | 5,173 | 51.4 | (50.0-52.9) | 2,030 | 21.4 | (20.4-22.4) | 2.41 |
| Urinary Bladder | 2,567 | 25.7 | (24.7-26.7) | 474 | 5.1 | (4.7-5.6) | 5.01 |
| Non-Hodgkin's Lymphoma | 1,815 | 17.7 | (16.9-18.6) | 630 | 6.6 | (6.0-7.1) | 2.69 |
| Kidney and Renal Pelvis | 1,310 | 12.3 | (11.6-13.0) | 400 | 3.9 | (3.6-4.4) | 3.12 |
| Leukemia | 1,201 | 12.0 | (11.3-12.7) | 699 | 7.3 | (6.8-7.9) | 1.64 |
| Lip, Oral Cavity and Pharynx | 1,171 | 10.8 | (10.2-11.5) | 296 | 2.9 | (2.6-3.3) | 3.75 |
| Pancreas | 1,075 | 10.6 | (10.0-11.3) | 1,017 | 10.2 | (9.6-10.9) | 1.04 |
| Skin | 2,023 | 19.2 | (18.4-20.1) | 298 | 2.8 | (2.5-3.2) | 6.75 |
| Corpus Uteri & Uterus NOS* | 1,033 | 18.8 | (17.6-20.0) | 155 | 3.0 | (2.5-3.5) | 6.29 |
| Ovary* | 734 | 13.4 | (12.5-14.5) | 456 | 8.5 | (7.7-9.3) | 1.59 |
| Thyroid Gland | 1,126 | 10.1 | (9.5-10.7) | 29 | 0.3 | (0.2-0.4) | 35.01 |
| Brain and Other Central Nervous System | 663 | 6.3 | (5.8-6.8) | 415 | 4.0 | (3.6-4.4) | 1.58 |
| Stomach | 639 | 6.4 | (5.9-6.9) | 346 | 3.6 | (3.2-4.0) | 1.77 |
| Liver and Intrahepatic Bile Ducts | 555 | 5.4 | (4.9-5.8) | 501 | 4.9 | (4.5-5.4) | 1.08 |
| Cervix Uteri* | 514 | 9.4 | (8.6-10.3) | 149 | 2.8 | (2.3-3.3) | 3.41 |
| Esophagus | 545 | 5.2 | (4.8-5.7) | 459 | 4.4 | (4.0-4.9) | 1.18 |
| Larynx | 391 | 3.7 | (3.3-4.1) | 108 | 1.1 | (0.9-1.3) | 3.50 |
| Multiple Myeloma | 453 | 4.4 | (4.0-4.9) | 341 | 3.4 | (3.1-3.8) | 1.29 |
| Hodgkin's Lymphoma | 279 | 2.5 | (2.2-2.8) | 37 | 0.4 | (0.2-0.5) | 7.08 |
| All Other Sites | 3,464 | 33.9 | (32.7-35.1) | 2,180 | 22.4 | (21.4-23.4) | 1.51 |
| Total | 49,963 | 479.9 | (475.6-484.2) | 19,379 | 196.5 | (193.7-199.4) | 2.44 |

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

INCIDENCE HIGHLIGHTS

- Lung And Bronchus Cancer was the leading type of cancer in Nevada from 2000 to 2004. This type of cancer accounted for 15.69% of all resident cancer cases during this period. The second leading type, Breast Cancer, accounted for 15.66% of all cancer incidence.
- When compared to national (2000-2004) incidence, Nevada had a much higher percentage of Lung & Bronchus Cancer, 15.7% vs 13.5% during the 2000-2004 period.
- Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer incidence rates for Whites, with a ratio of 0.91. This means that for every 100 White cancer cases Blacks would be expected to have 91 cases. Asians, Hispanics and Native Americans had comparison ratios of 0.57, 0.50 and 0.25, respectively, for Nevada from 2000 to 2004.
- Stomach cancer had the highest age-adjusted incidence comparison ratio for Blacks when compared to Whites in Nevada from 2000 to 2004 with a comparison ratio of 1.98. This means that for every 100 White Stomach cancer cases Blacks would be expected to have 198 cases. Liver and Intrahepatic Bile Ducts cancer had the highest age-adjusted comparison ratio for Asians when compared to Whites in Nevada from 2000 to 2004 at a 2.70 ratio.
- Skin cancer had the lowest age-adjusted incidence comparison ratio for Blacks and Hispanics at 0.13 and 0.12, respectively. Meaning for every 100 White Skin cancer cases Blacks and Hispanics would be expected to have 13 and 12 cases respectively.
- Hodgkin's Lymphoma had the lowest median age at time of diagnosis for Nevada residents from 2000 to 2004 at 40 years. The median age for females diagnosed with Hodgkin's Lymphoma was 38 years, while for males it was 42 years.
- Urinary Bladder cancer had the lowest median age at time of diagnosis for Nevada residents from 2000 to 2004 at 71 years. The median age for males and females diagnosed with Urinary Bladder was 71 years.





Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the SEER region.

Figure 5. Comparison of Age-Adjusted (2000) Incidence Rates of Blacks compared to Whites, Nevada Residents, 2000-2004







Figure 6. Comparison of Age-Adjusted (2000) Incidence Rates of Native Americans compared to Whites, Nevada Residents, 2000-2004



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 7. Comparison of Age-Adjusted (2000) Incidence Rates of Asians compared to Whites, Nevada Residents, 2000-2004










Table 5. Nevada Incidence by Type of Cancer, Nevada (2000-2004) andSEER-17 (2000-2004)

| T (A | Incidence (2000-2004) | | | SEER-17 (2000-2004) | | |
|--|-----------------------|--------|---------------|---------------------|--------|---------------|
| Type of Cancer | Number | Rate* | 95% C.I. | Number | Rate* | 95% C.I. |
| Total | 49,963 | 480.00 | (475.6-484.2) | 1,671,265 | 469.97 | (469.3-470.7) |
| Lip, Oral Cavity and Pharynx | 1,171 | 11.00 | (10.2-11.5) | 37,724 | 10.47 | (10.4-10.6 |
| Lip | 48 | 0.46 | (0.3-0.6) | 3,069 | 0.86 | (0.8-0.9 |
| Base of Tongue | 184 | 1.70 | (1.4-1.9) | 4,664 | 1.29 | (1.3-1.3) |
| Other & Unspecified Parts of Tongue | 182 | 1.70 | (1.4-1.9) | 5,264 | 1.46 | (1.4-1.5 |
| Parotid Gland | 96 | 0.96 | (0.8-1.2) | 3,478 | 0.97 | (0.9-1.0 |
| Other & Unspecified Major Salivary glands | 30 | 0.28 | (0.2-0.4) | 798 | 0.22 | (0.2-0.2 |
| Floor of Mouth | 89 | 0.83 | (0.7-1.0) | 2,490 | 0.69 | (0.7-0.7 |
| Gum | 33 | 0.31 | (0.2-0.4) | 1,355 | 0.38 | (0.4-0.4 |
| Palate | 47 | 0.45 | (0.3-0.6) | 1,965 | 0.55 | (0.5-0.6 |
| Other & Unspecified Parts of Mouth | 61 | 0.58 | (0.4-0.8) | 2,244 | 0.63 | (0.6-0.7 |
| Nasopharynx | 70 | 0.64 | (0.5-0.8) | 2,408 | 0.66 | (0.6-0.7 |
| Tonsil | 162 | 1.50 | (1.2-1.7) | 5,356 | 1.46 | (1.4-1.5 |
| Oropharynx | 48 | 0.43 | (0.3-0.6) | 1,151 | 0.32 | (0.3-0.3 |
| Pyriform Sinus | 45 | 0.44 | (0.3-0.6) | 1,528 | 0.43 | (0.4-0.5 |
| Hypopharynx | 41 | 0.37 | (0.3-0.5) | 1,094 | 0.31 | (0.3-0.3 |
| Other & Unspecified Oral (Buccal) Cavity & Pharynx | 35 | 0.33 | (0.2-0.5) | 0 | | |
| Digestive System | 8,452 | 84.00 | (81.8-85.4) | 315,879 | 89.48 | (89.2-89.8 |
| Esophagus | 545 | 5.20 | (4.8-5.7) | 16,224 | 4.60 | (4.5-4.7 |
| Stomach | 639 | 6.40 | (5.9-6.9) | 28,577 | 8.10 | (8.0-8.2 |
| Small Intestine | 140 | 1.30 | (1.1-1.6) | 6,354 | 1.79 | (1.7-1.8 |
| Colon (excluding Rectum) | 3,593 | 36.00 | (35.1-37.5) | 131,311 | 37.35 | (37.2-37.6 |
| Cecum | 827 | 8.50 | (7.9-9.1) | 29,637 | 8.46 | (8.4-8.6 |
| Appendix | 50 | 0.49 | (0.4-0.7) | 1,929 | 0.53 | (0.5-0.6 |
| Ascending Colon | 543 | 5.60 | (5.1-6.1) | 22,814 | 6.52 | (6.4-6.6 |
| Hepatic Flexure | 147 | 1.50 | (1.3-1.8) | 7,111 | 2.03 | (2.0-2.1 |
| Transverse Colon | 263 | 2.70 | (2.3-3.0) | 11,668 | 3.33 | (3.3-3.4 |
| Splenic Flexure | 97 | 0.91 | (0.7-1.1) | 4,797 | 1.36 | (1.3-1.4 |
| Descending Colon | 182 | 1.80 | (1.5-2.1) | 7,866 | 2.23 | (2.2-2.3 |
| Sigmoid Colon | 1,038 | 10.00 | (9.5-10.8) | 37,928 | 10.74 | (10.6-10.9 |
| Large Intestine, NOS | 446 | 4.70 | (4.3-5.2) | 7,561 | 2.15 | (2.1-2.2 |
| Rectum | 959 | 9.20 | (8.6-9.8) | 36,060 | 10.13 | (10.0-10.2 |
| Rectosigmoid Junction | 474 | 4.60 | (4.2-5.0) | 14,666 | 4.14 | (4.1-4.2 |
| Anus, Anal Canal and Anorectum | 147 | 1.40 | (1.2-1.6) | 5,330 | 1.48 | (1.4-1.5 |
| Liver | 503 | 4.80 | (4.4-5.3) | 19,944 | 5.57 | (5.5-5.7 |
| Intrahepatic Bile Ducts | 52 | 0.53 | (0.4-0.7) | 2,133 | 0.61 | (0.6-0.6 |
| Gallbladder | 68 | 0.68 | (0.5-0.9) | 4,124 | 1.18 | (1.1-1.2 |
| Other & Unspecified Biliary Tract | 160 | 1.60 | (1.4-1.9) | 5,924 | 1.69 | (1.6-1.7 |
| Pancreas | 1,075 | 11.00 | (10.0-11.3) | 39,880 | 11.35 | (11.2-11.5 |
| Retroperitoneum | 42 | 0.38 | (0.3-0.5) | 1,458 | 0.40 | (0.4-0.4 |
| Peritoneum, Omentum and Mesentery | 34 | 0.32 | (0.2-0.5) | 2,185 | 0.62 | (0.6-0.7 |
| Other Digestive Organs | 21 | 0.20 | (0.1-0.3) | 1,704 | 0.48 | (0.5-0.5 |
| Respiratory System | 8,401 | 81.00 | (79.3-82.9) | 241,947 | 69.09 | (68.8-69.4 |
| Nasal Cavity and Middle Ear | 40 | 0.38 | (0.3-0.5) | 1,377 | 0.38 | (0.4-0.4 |
| Accessory Sinuses | 33 | 0.31 | (0.2-0.4) | 1,572 | 0.44 | (0.4-0.5 |
| Larynx | 391 | 3.70 | (3.3-4.1) | 13,225 | 3.72 | (3.7-3.8 |
| Lung and Bronchus | 7,839 | 76.00 | (74.1-77.5) | 225,459 | 64.47 | (64.2-64.7 |
| Pleura | 81 | 0.79 | (0.6-1.0) | 136 | 0.04 | (0.0-0.1 |
| Trachea | 6 | | | 250 | 0.07 | (0.1-0.1 |
| Mediastinum and Other Respiratory Organs | 11 | 0.10 | (0.0-0.2) | 650 | 0.17 | (0.2-0.2 |
| Bones, Joints and Articular Cartilage | 80 | 0.76 | (0.6-1.0) | 4,741 | 1.29 | (1.3-1.3 |
| Bones, Joints & Articular Cartilage of Limbs | 40 | 0.38 | (0.3-0.5) | 2,126 | 0.57 | (0.6-0.6 |
| Bones, Joints & Articular Cartilage of Other & Unspec Site | 40 | 0.39 | (0.3-0.6) | 2,615 | 0.72 | (0.7-0.7 |
| Soft Tissue (Including Heart) | 265 | 2.60 | (2.3-2.9) | 11,229 | 3.08 | (3.0-3.1 |
| Heart | 3 | | | 155 | 0.04 | (0.0-0.1 |
| Peripheral Nerves & Autonomic Nervous System | 4 | | | 549 | 0.15 | (0.1-0.2 |
| Connective, Subcutaneous & Other Soft Tissues | 258 | 2.50 | (2.2-2.8) | 11,675 | 3.21 | (3.2-3.3 |

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.






* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

REPORT ON CANCER IN NEVADA 2000-2004

Table 6. Nevada Incidence by Type of Cancer and Gender,Nevada, 2000-2004



* Those of unknown gender are not shown separately, but are included in the total.

** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 genderspecific population and age-adjusted to the 2000 US Standard population.

Note: The "----" is used for rates calculated on numbers less than ten.

Table 6. Nevada Incidence by Type of Cancer and Gender,Nevada, 2000-2004 (Continued)

| Turne of Conner | Tota | Total* | | е | Female | |
|---|------------|--------------|------------|--------------|------------|--------------|
| Type of Cancer | Number | Rate** | Number | Rate** | Number | Rate** |
| Total | 49,963 | 480.00 | 26,366 | 538.00 | 23,591 | 436.00 |
| Skin (Excluding Basal And Squamous) | 2,023 | 19.00 | 1,227 | 24.00 | 795 | 15.00 |
| Melanomas Of The Skin | 2,023 | 19.00 | 1,227 | 24.00 | 795 | 15.00 |
| Other Non-Epithelial Skin | 0 | | 0 | | 0 | |
| Breast | 7,824 | 73.00 | 81 | 1.70 | 7,742 | 141.00 |
| Female Genital System | 2,474 | 23.00 | 0 | | 2,474 | 45.00 |
| Cervix Uteri | 514 | 4.70 | 0 | | 514 | 9.40 |
| Corpus Uteri | 986 | 9.20 | 0 | | 986 | 18.00 |
| Uterus, NOS | 47 | 0.46 | 0 | | 47 | 0.88 |
| Ovary | 734 | 7.00 | 0 | | 734 | 13.00 |
| Vagina | 33 | 0.33 | 0 | | 33 | 0.62 |
| Vulva | 132 | 1.30 | 0 | | 132 | 2.50 |
| Placenta | 4 | | 0 | | 4 | |
| Other Female Genital Organs | 24 | 0.23 | 0 | | 24 | 0.44 |
| Male Genital System | 7,880 | 75.00 | 7,880 | 158.00 | 0 | |
| Prostate | 7,569 | 72.00 | 7,569 | 153.00 | 0 | |
| Testis | 268 | 2.40 | 268 | 4.70 | 0 | |
| Penis | 27 | 0.27 | 27 | 0.62 | 0 | |
| Other Male Genital Organs | 16 | 0.15 | 16 | 0.32 | 0 | |
| Urinary System | 3,978 | 39.00 | 2,892 | 61.00 | 1,086 | 20.00 |
| Urinary Bladder | 2,567 | 26.00 | 1,981 | 43.00 | 586 | 11.00 |
| Kidney | 1,237 | 12.00 | 801 | 16.00 | 436 | 8.00 |
| Renal Pelvis | 73 | 0.70 | 42 | 0.86 | 31 | 0.56 |
| Ureter | 56 | 0.54 | 39 | 0.79 | 17 | 0.32 |
| Other Urinary Organs | 45 | 0.47 | 29 | 0.63 | 16 | 0.31 |
| Eye and Orbit | 63 | 0.61 | 39 | 0.78 | 24 | 0.44 |
| Brain and Other Central Nervous System | 663 | 6.30 | 385 | 7.50 | 278 | 5.20 |
| Brain | 611 | 5.80 | 358 | 6.90 | 253 | 4.70 |
| Meninges | 25 | 0.24 | 12 | 0.22 | 13 | 0.24 |
| Spinal Cord, Cranial Nerves, & Other Parts of CNS | 27 | 0.25 | 15 | 0.30 | 12 | 0.22 |
| Endocrine System | 1,178 | 11.00 | 276 | 5.10 | 902 | 16.00 |
| Thyroid Gland | 1,126 | 10.00 | 245 | 4.40 | 881 | 16.00 |
| Adrenal Gland | 19 | 0.19 | 14 | 0.32 | 5 | |
| Other Endocrine (Including Thymus) | 33 | 0.32 | 17 | 0.36 | 16 | 0.30 |
| Hodgkin's Lymphoma | 279 | 2.50 | 151 | 2.70 | 128 | 2.30 |
| Non-Hodgkin's Lymphoma | 1,815 | 18.00 | 1,035 | 21.00 | 780 | 15.00 |
| Multiple Myeloma | 453 | 4.40 | 264 | 5.50 | 189 | 3.50 |
| Leukemia | 1,201 | 12.00 | 700 | 15.00 | 500 | 9.60 |
| Lymphocytic | 553 | 5.40 1.30 | 333 | 7.00 | 220 | 4.20 |
| Acute Lymphocytic | 137 | | 69 225 | 1.30 | 68 146 | 1.30 |
| Chronic Lymphocytic | 381 | 3.80 | 235 | 5.10 | 146 | 2.80 |
| Other Lymphocytic | 35 | 0.33 | 29 | 0.57 | 6 | |
| Myeloid and Monocytic Acute Myeloid | 565 396 | 5.60 3.90 | 319 230 | 6.70 4.90 | 245 165 | 4.70 3.10 |
| | | | | | | |
| Acute Monocytic | 22 | 0.24 | 10 | 0.20 | 12 | 0.28 |
| Chronic Myeloid Other Myeloid/Monocytic | 133 14 | 1.30 0.14 | 74 5 | 1.60 | 59 9 | 1.10 |
| Other | 83 | 0.14 0.91 | 5 48 | 1.20 | 9 35 | 0.69 |
| | | | | | | |
| Other Acute | 39 | 0.40 | 26 | 0.59 | 13 | 0.25 |
| Aleukemic, Subleukemic and NOS | 44 | 0.51 | 22 | 0.59 | 22 | 0.44 |
| Mesothelioma | 0 0 | | 0 0 | | 0 0 | |
| Kaposi Sarcoma | | | | | | |

* Those of unknown gender are not shown separately, but are included in the total.

** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer,
Nevada, 2000-2004

| Type of Cancer | Total | In situ | Localized | Regional | Distant | Unstaged |
|---|--------------|---------|-------------|-------------|--------------|--------------|
| Total | 49,963 | 2,237 | 18,170 | 7,901 | 8,259 | 13,396 |
| Lip, Oral Cavity and Pharynx | 1,171 | | 331 | 400 | 92 | 348 |
| Lip | 48 | | 35 | 4 | 0 | 9 |
| Base of Tongue | 184 | | 28 | 88 | 16 | 52 |
| Other & Unspecified Parts of Tongue | 182 | | 83 | 41 | 4 | 54 |
| Parotid Gland | 96 | | 35 | 22 | 5 | 34 |
| Other & Unspecified Major Salivary glands | 30 | | 8 | 8 | 1 | 13 |
| Floor of Mouth | 89 | | 31 | 31 | 10 | 17 |
| Gum | 33 | | 5 | 13 | 6 | 9 |
| Palate | 47 | | 19 | 13 | 1 | 14 |
| Other & Unspecified Parts of Mouth | 61 | | 18 | 13 | 9 | 21 |
| Nasopharynx | 70 | | 8 | 22 | 12 | 28 |
| Tonsil | 162 | | 33 | 79 | 5 | 45 |
| Oropharynx | 48 | | 7 | 16 | 10 | 15 |
| Pyriform Sinus | 45 | | 8 | 26 | 4 | 7 |
| Hypopharynx | 41 | | 12 | 15 | 3 | 11 |
| Other & Unspecified Oral (Buccal) Cavity & Pharynx | 35 | | 1 | 9 | 6 | 19 |
| Digestive System | 8,452 545 | | 2,027 91 | 2,298 88 | 1,640 130 | 2,487 236 |
| Esophagus Stomach | 639 | | 117 | 163 | 130 | 230 |
| Stomach Small Intestine | 140 | | 32 | 45 | 29 | 34 |
| Colon (excluding Rectum) | 3,593 | | 1,005 | 1,230 | 610 | 748 |
| Cecum | 3,333 827 | | 214 | 332 | 162 | 119 |
| Appendix | 50 | | 18 | 17 | 9 | 6 |
| Ascending Colon | 543 | | 152 | 215 | 64 | 112 |
| Hepatic Flexure | 147 | | 45 | 53 | 23 | 26 |
| Transverse Colon | 263 | | 75 | 104 | 39 | 45 |
| Splenic Flexure | 97 | | 27 | 44 | 13 | 13 |
| Descending Colon | 182 | | 59 | 71 | 23 | 29 |
| Sigmoid Colon | 1,038 | | 358 | 336 | 177 | 167 |
| Large Intestine, NOS | 446 | | 57 | 58 | 100 | 231 |
| Rectum | 959 | | 320 | 256 | 107 | 276 |
| Rectosigmoid Junction | 474 | | 136 | 168 | 86 | 84 |
| Anus, Anal Canal and Anorectum | 147 | | 64 | 24 | 12 | 47 |
| Liver | 503 | | 129 | 34 | 81 | 259 |
| Intrahepatic Bile Ducts | 52 | | 8 | 10 | 4 | 30 |
| Gallbladder | 68 | | 14 | 19 | 20 | 15 |
| Other & Unspecified Biliary Tract | 160 | | 27 | 38 | 20 | 75 |
| Pancreas | 1,075 | | 71 | 210 | 376 | 418 |
| Retroperitoneum | 42 | | 10 | 7 | 9 | 16 |
| Peritoneum, Omentum and Mesentery | 34 | | 3 | 4 | 14 | 13 |
| Other Digestive Organs | 21 | | 0 | 2 | 7 | 12 |
| Respiratory System | 8,401 | | 1,329 | 1,497 | 2,624 | 2,951 |
| Nasal Cavity and Middle Ear | 40 | | 20 | 3 | 1 | 16 |
| Accessory Sinuses | 33 | | 7 | 11 | 4 | 11 |
| Larynx | 391 | | 152 | 65 | 25 | 149 |
| Lung and Bronchus | 7,839 | | 1,132 | 1,397 | 2,573 | 2,737 |
| Pleura | 81 | | 15 | 18 | 19 | 29 |
| Trachea | 6 | | 1 | 2 | 0 | 3 |
| Mediastinum and Other Respiratory Organs | 11 | | 2 | 1 | 2 | 6 |
| Bones, Joints and Articular Cartilage | 80 | | 28 | 16 | 12 | 24 |
| Bones, Joints & Articular Cartilage of Limbs | 40 | | 18 | 5 | 5 | 12 |
| Bones, Joints & Articular Cartilage of Other & Unspec Sites | 40 | | 10 | 11 | 7 | 12 |
| Soft Tissue (Including Heart) | 265 | | 100 | 23 | 34 | 108 |
| Heart | 3 | | 1 | 1 | 0 | 1 |
| Peripheral Nerves & Autonomic Nervous System | 4 | | 1 | 1 | 1 | 1 |
| Connective, Subcutaneous & Other Soft Tissues | 258 | | 98 | 21 | 33 | 106 |

| Type of Cancer | Total | In situ | Localized | Regional | Distant | Unstaged |
|---|--------|---------|-----------|----------|---------|----------|
| Total | 49,963 | 2,237 | 18,170 | 7,901 | 8,259 | 13,396 |
| Skin (Excluding Basal And Squamous) | 2,023 | | 1,304 | 146 | 77 | 496 |
| Melanomas Of The Skin | 2,023 | | 1,304 | 146 | 77 | 496 |
| Other Non-Epithelial Skin | 0 | | 0 | 0 | 0 | 0 |
| Breast | 7,824 | 1,243 | 3,254 | 1,676 | 336 | 1,315 |
| Female Genital System | 2,474 | | 1,074 | 442 | 412 | 546 |
| Cervix Uteri | 514 | | 248 | 128 | 40 | 98 |
| Corpus Uteri | 986 | | 616 | 135 | 44 | 191 |
| Uterus, NOS | 47 | | 5 | 7 | 15 | 20 |
| Ovary | 734 | | 113 | 135 | 302 | 184 |
| Vagina | 33 | | 11 | 9 | 3 | 10 |
| Vulva | 132 | | 76 | 23 | 3 | 30 |
| Placenta | 4 | | 1 | 1 | 0 | 2 |
| Other Female Genital Organs | 24 | | 4 | 4 | 5 | 11 |
| Male Genital System | 7,880 | | 5,599 | 630 | 264 | 1,387 |
| Prostate | 7,569 | | 5,423 | 587 | 232 | 1,327 |
| Testis | 268 | | 159 | 38 | 31 | 40 |
| Penis | 27 | | 10 | 5 | 1 | 11 |
| Other Male Genital Organs | 16 | | 7 | 0 | 0 | 9 |
| Urinary System | 3,978 | 994 | 1,520 | 384 | 283 | 797 |
| Urinary Bladder | 2,567 | 994 | 855 | 194 | 85 | 439 |
| Kidney | 1,237 | | 590 | 160 | 190 | 297 |
| Renal Pelvis | 73 | | 34 | 18 | 4 | 17 |
| Ureter | 56 | | 28 | 8 | 4 | 16 |
| Other Urinary Organs | 45 | | 13 | 4 | 0 | 28 |
| Eye and Orbit | 63 | | 27 | 2 | 2 | 32 |
| Brain and Other Central Nervous System | 663 | | 392 | 16 | 6 | 249 |
| Brain | 611 | | 374 | 14 | 6 | 217 |
| Meninges | 25 | | 9 | 2 | 0 | 14 |
| Spinal Cord, Cranial Nerves, & Other Parts of CNS | 27 | | 9 | 0 | 0 | 18 |
| Endocrine System | 1,178 | | 713 | 186 | 40 | 239 |
| Thyroid Gland | 1,126 | | 693 | 180 | 34 | 219 |
| Adrenal Gland | 19 | | 4 | 3 | 6 | 6 |
| Other Endocrine (Including Thymus) | 33 | | 16 | 3 | 0 | 14 |
| Hodgkin's Lymphoma | 279 | | 85 | 38 | 52 | 104 |
| Non-Hodgkin's Lymphoma | 1,815 | | 387 | 147 | 554 | 727 |
| Multiple Myeloma | 453 | | 0 | 0 | 409 | 44 |
| Leukemia | 1,201 | | 0 | 0 | 1,123 | 78 |
| Lymphocytic | 553 | | 0 | 0 | 525 | 28 |
| Acute Lymphocytic | 137 | | 0 | 0 | 132 | 5 |
| Chronic Lymphocytic | 381 | | 0 | 0 | 359 | 22 |
| Other Lymphocytic | 35 | | 0 | 0 | 34 | 1 |
| Myeloid and Monocytic | 565 | | 0 | 0 | 529 | 36 |
| Acute Myeloid | 396 | | 0 | 0 | 376 | 20 |
| Acute Monocytic | 22 | | 0 | 0 | 20 | 2 |
| Chronic Myeloid | 133 | | 0 | 0 | 122 | 11 |
| Other Myeloid/Monocytic | 14 | | 0 | 0 | 11 | 3 |
| Other | 83 | | 0 | 0 | 69 | 14 |
| Other Acute | 39 | | 0 | 0 | 36 | 3 |
| Aleukemic, Subleukemic and NOS | 44 | | 0 | 0 | 33 | 11 |
| Mesothelioma | 0 | | 0 | 0 | 0 | 0 |
| Kaposi Sarcoma | 0 | | 0 | 0 | 0 | 0 |
| Other, III-Defined and Unspecified Sites | 1,763 | | 0 | 0 | 299 | 1,464 |

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer,
Nevada, 2000-2004 (Continued)

Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence,
Nevada Residents, 2000-2004

| Rank Type of Cancer Nevada Total Clark Washoe All Other Counties 1 Lung And Bronchus Incidence 7.839 5.515 1,402 1,180 1 Lung And Bronchus Incidence 7.839 5.515 1,402 1,180 95% C.1 (74.1-77.5) (76.0-80.3) (77.8-86.6) (67.0-75.3) 2 Breast Incidence 7.824 5,397 1,243 1,153 3 Prostate Incidence 7.824 5,397 (71.5-80.1) (65.3-7.5.) 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 7,569 5,145 1,166 1,018 5 Urinary Bladder Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,567 1,727 394 445 5< | | | | | County/Region | n of Residence | |
|---|------|------------------------------|-----------|---------------|---------------|----------------|---------------|
| Rate* 75.77 78.14 82.13 71.05 95% C.I. (74.1-77.5) (76.0-80.3) (77.8-86.6) (67.0-75.3) 2 Breast Incidence 7,824 5,397 1,243 1,153 3 Prostate Incidence 7,824 5,397 (71.7-80.1) (65.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 7,573 (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 7110 5 Urinary Bladder Incidence 2,567 1,727 394 445 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,023 1,505 301 247 6 Skin Incidence 2,027 1,727 394 445 7 Non-Hodgkin's Lymphoma 1nc | Rank | Type of Cancer | , | | Clark | Washoe | |
| 95% C.I. (74.1-77.5) (76.0-80.3) (77.8-86.6) (67.0-75.3) 2 Breast Incidence 7,824 5,397 1,243 1,153 2 Breast Incidence 7,824 5,397 1,243 1,153 3 Prostate Incidence 7,803 73.64 75.72 69.33 3 Prostate Incidence 7,569 5,145 1,166 1,018 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 2,567 1,727 394 445 5 Urinary Bladder Incidence 2,023 1,505 301 247 6 Skin Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymp | 1 | Lung And Bronchus | Incidence | 7,839 | 5,515 | 1,402 | 1,180 |
| 2 Breast Incidence 7,824 5,397 1,243 1,153 Rate* 73.33 73.64 75.72 69.33 95% C.I. (71.7-75.0) (71.7-75.7) (71.5-80.1) (65.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 </td <td></td> <td></td> <td>Rate*</td> <td>75.77</td> <td>78.14</td> <td>82.13</td> <td>71.05</td> | | | Rate* | 75.77 | 78.14 | 82.13 | 71.05 |
| Rate* 73.33 73.64 75.72 69.33 95% C.I. (71.7-75.0) (71.7-75.7) (71.5-80.1) (65.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 3 Prostate Incidence 7,569 5,145 1,166 1,018 4 Colorectal Incidence 5,173 3,628 832 710 4 Colorectal Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 2,567 1,727 394 445 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,023 1,505 301 247 6 Skin Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 1,815< | | | 95% C.I. | (74.1-77.5) | (76.0-80.3) | (77.8-86.6) | (67.0-75.3) |
| 95% C.I. (71.7-75.0) (71.7-75.7) (71.5-80.1) (66.3-73.5) 3 Prostate Incidence 7,569 5,145 1,166 1,018 3 Prostate Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 8322 710 4 Colorectal Incidence 5,173 3,628 832 710 5 Urinary Bladder Incidence 2,567 1,727 394 445 5 Urinary Bladder Incidence 2,567 1,727 394 28.18 6 Skin Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 | 2 | Breast | Incidence | 7,824 | 5,397 | 1,243 | 1,153 |
| 3 Prostate Incidence 7,569 5,145 1,166 1,018 Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.6-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 </td <td></td> <td></td> <td>Rate*</td> <td>73.33</td> <td>73.64</td> <td>75.72</td> <td>69.33</td> | | | Rate* | 73.33 | 73.64 | 75.72 | 69.33 |
| Rate* 71.75 70.97 72.02 62.17 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,023 1,505 301 247 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 5% (13.6-17.6) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 84t* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) | | | 95% C.I. | (71.7-75.0) | (71.7-75.7) | (71.5-80.1) | (65.3-73.5) |
| 95% C.I. (70.1-73.4) (69.0-73.0) (67.9-76.4) (58.4-66.2) 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Skin Incidence 2,568 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 8 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 <t< td=""><td>3</td><td>Prostate</td><td>Incidence</td><td>7,569</td><td>5,145</td><td>1,166</td><td>1,018</td></t<> | 3 | Prostate | Incidence | 7,569 | 5,145 | 1,166 | 1,018 |
| 4 Colorectal Incidence 5,173 3,628 832 710 Rate* 51.43 52.76 52.68 44.33 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | Rate* | 71.75 | 70.97 | 72.02 | 62.17 |
| Rate* 51.43 52.76 52.68 44.33 95% C.1. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 6 Rate* 25.68 25.12 25.23 28.18 95% C.1. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 7 Non-Hodgkin's Lymphoma Incidence 19.20 20.77 17.48 15.52 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | 95% C.I. | (70.1-73.4) | (69.0-73.0) | (67.9-76.4) | (58.4-66.2) |
| 95% C.I. (50.0-52.9) (51.0-54.6) (49.1-56.5) (41.1-47.8) 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | 4 | Colorectal | Incidence | 5,173 | 3,628 | 832 | 710 |
| 5 Urinary Bladder Incidence 2,567 1,727 394 445 Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | Rate* | 51.43 | 52.76 | 52.68 | 44.33 |
| Rate* 25.68 25.12 25.23 28.18 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | 95% C.I. | (50.0-52.9) | (51.0-54.6) | (49.1-56.5) | (41.1-47.8) |
| 95% C.I. (24.7-26.7) (23.9-26.4) (22.8-28.0) (25.6-31.0) 6 Skin Incidence 2,023 1,505 301 247 6 Skin Incidence 2,023 1,505 301 247 7 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | 5 | Urinary Bladder | Incidence | 2,567 | 1,727 | 394 | 445 |
| 6 Skin Incidence 2,023 1,505 301 247 Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | Rate* | 25.68 | 25.12 | 25.23 | 28.18 |
| Rate* 19.20 20.77 17.48 15.52 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | 95% C.I. | (24.7-26.7) | (23.9-26.4) | (22.8-28.0) | (25.6-31.0) |
| 95% C.I. (18.4-20.1) (19.7-21.9) (15.5-19.7) (13.6-17.6) 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | 6 | Skin | Incidence | 2,023 | 1,505 | 301 | 247 |
| 7 Non-Hodgkin's Lymphoma Incidence 1,815 1,274 293 215 Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | Rate* | 19.20 | 20.77 | 17.48 | 15.52 |
| Rate* 17.69 18.20 17.58 13.82 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | 95% C.I. | (18.4-20.1) | (19.7-21.9) | (15.5-19.7) | (13.6-17.6) |
| 95% C.I. (16.9-18.6) (17.2-19.3) (15.6-19.8) (12.0-15.9) 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | 7 | Non-Hodgkin's Lymphoma | Incidence | 1,815 | 1,274 | 293 | 215 |
| 8 Kidney And Renal Pelvis Incidence 1,310 910 225 176 | | | Rate* | 17.69 | 18.20 | 17.58 | 13.82 |
| | | | 95% C.I. | (16.9-18.6) | (17.2-19.3) | (15.6-19.8) | (12.0-15.9) |
| | 8 | Kidney And Renal Pelvis | Incidence | 1,310 | 910 | 225 | 176 |
| Rate* 12.30 13.34 13.39 10.79 | | | Rate* | 12.30 | 13.34 | 13.39 | 10.79 |
| 95% C.I. (11.6-13.0) (12.5-14.3) (11.7-15.3) (9.2-12.6) | | | 95% C.I. | (11.6-13.0) | (12.5-14.3) | (11.7-15.3) | (9.2-12.6) |
| 9 Leukemia Incidence 1,201 909 196 168 | 9 | Leukemia | Incidence | 1,201 | 909 | 196 | 168 |
| Rate* 11.98 12.40 10.65 10.03 | | | Rate* | 11.98 | 12.40 | 10.65 | 10.03 |
| 95% C.I. (11.3-12.7) (11.6-13.3) (9.2-12.3) (8.6-11.7) | | | 95% C.I. | (11.3-12.7) | (11.6-13.3) | (9.2-12.3) | (8.6-11.7) |
| 10 Lip, Oral Cavity And Pharynx Incidence 1,171 820 182 157 | 10 | Lip, Oral Cavity And Pharynx | Incidence | 1,171 | 820 | 182 | 157 |
| Rate* 10.85 11.05 10.59 9.57 | | | Rate* | 10.85 | 11.05 | 10.59 | 9.57 |
| 95% C.I. (10.2-11.5) (10.3-11.9) (9.1-12.3) (8.1-11.2) | | | 95% C.I. | (10.2-11.5) | (10.3-11.9) | (9.1-12.3) | (8.1-11.2) |
| Total Incidence 49,963 34,851 8,080 7,004 | | Total | Incidence | 49,963 | 34,851 | 8,080 | 7,004 |
| Rate* 479.88 487.85 489.61 432.94 | | | Rate* | 479.88 | 487.85 | 489.61 | 432.94 |
| 95% C.I. (475.6-484.2) (482.6-493.1) (478.8-500.6) (422.7-443.8) | | | 95% C.I. | (475.6-484.2) | (482.6-493.1) | (478.8-500.6) | (422.7-443.8) |

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 2000-2004

| Ranking | | | | | Age Group | | | | |
|---------|-----------------|----------------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Nanking | 0-14 | 15-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 | 75+ | Total |
| 1 | Leukemia | Thyroid Gland | Thyroid Gland | Breast | Breast | Prostate | Prostate | Lung & Bronchus | Lung & Bronchus |
| | 98 | 56 | 175 | 762 | 1,629 | 2,072 | 3,097 | 2,376 | 7,839 |
| | 30.1% | 14.7% | 17.0% | 28.2% | 25.6% | 17.7% | 21.0% | 18.7% | 15.7% |
| 2 | Brain and OCNS | Skin | Skin | Skin | Lung & Bronchus | Breast | Lung & Bronchus | Prostate | Breast |
| | 57 | 43 | 136 | 271 | 624 | 2,046 | 2,822 | 1,834 | 7,824 |
| | 17.5% | 11.3% | 13.2% | 10.0% | 9.8% | 17.5% | 19.2% | 14.4% | 15.7% |
| 3 | NHL | HL | Breast | Thyroid Gland | Colorectal | Lung & Bronchus | Breast | Colorectal | Prostate |
| | 20 | 37 | 114 | 256 | 563 | 1,898 | 1,880 | 1,775 | 7,568 |
| | 6.1% | 9.7% | 11.1% | 9.5% | 8.8% | 16.2% | 12.8% | 13.9% | 15.1% |
| 4 | KRP | Leukemia | Cervix Uteri | Colorectal | Prostate | Colorectal | Colorectal | Breast | Colorectal |
| | 18 | 29 | 73 | 168 | 540 | 1,080 | 1,539 | 1,385 | 5,173 |
| | 5.5% | 7.6% | 7.1% | 6.2% | 8.5% | 9.2% | 10.5% | 10.9% | 10.4% |
| 5 | HL | Brain and OCNS | NHL | NHL | Skin | Urinary Bladder | Urinary Bladder | Urinary Bladder | Urinary Bladder |
| | 17 | 28 | 61 | 131 | 359 | 492 | 870 | 957 | 2,567 |
| | 5.2% | 7.4% | 5.9% | 4.9% | 5.6% | 4.2% | 5.9% | 7.5% | 5.1% |
| 6 | Liver and IBD | NHL | HL | Cervix Uteri | Thyroid Gland | NHL | NHL | NHL | Skin |
| | 11 | 23 | 54 | 127 | 269 | 384 | 463 | 511 | 2,023 |
| | 3.4% | 6.1% | 5.2% | 4.7% | 4.2% | 3.3% | 3.1% | 4.0% | 4.0% |
| 7 | Skin | Ovary | Colorectal | Lung & Bronchus | LOCP | Skin | Skin | Skin | NHL |
| | 10 | 9 | 42 | 105 | 222 | 382 | 434 | 388 | 1,815 |
| | 3.1% | 2.4% | 4.1% | 3.9% | 3.5% | 3.3% | 2.9% | 3.0% | 3.6% |
| 8 | LOCP | LOCP | Brain and OCNS | CU & Uterus NOS | NHL | KRP | KRP | Leukemia | KRP |
| | 4 | 7 | 42 | 85 | 222 | 362 | 366 | 372 | 1,310 |
| | 1.2% | 1.8% | 4.1% | 3.2% | 3.5% | 3.1% | 2.5% | 2.9% | 2.6% |
| 9 | Ovary | Breast | Leukemia | KRP | CU & Uterus NOS | LOCP | Pancreas | Pancreas | Leukemia |
| | 2 | 7 | 37 | 81 | 200 | 355 | 310 | 366 | 1,200 |
| | 0.6% | 1.8% | 3.6% | 3.0% | 3.1% | 3.0% | 2.1% | 2.9% | 2.4% |
| 10 | Urinary Bladder | Colorectal | Ovary | LOCP | KRP | CU & Uterus NOS | LOCP | KRP | LOCP |
| | 2 | 5 | 29 | 68 | 200 | 281 | 304 | 271 | 1,171 |
| | 0.6% | 1.3% | 2.8% | 2.5% | 3.1% | 2.4% | 2.1% | 2.1% | 2.3% |
| Sum | 239 | 244 | 763 | 2,054 | 4,828 | 9,352 | 12,085 | 10,235 | 38,490 |
| Percent | 73.3% | 64.2% | 74.1% | 76.1% | 75.8% | 80.0% | 82.1% | 80.4% | 77.0% |
| Total | 326 | 380 | 1,029 | 2,698 | 6,373 | 11,689 | 14,727 | 12,736 | 49,958 |
| | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 10. Median Age at Time of Diagnosis by Leading Types of Cancer and
Race/Ethnicity, Nevada Residents, 2000-2004


| | Race/Ethnicity | | | | | | | | | | |
|--------------------------------------|----------------|-------|--------------------|-------|----------|-------|--|--|--|--|--|
| Type of Cancer | White | Black | Native American | Asian | Hispanic | Total | | | | | |
| Lung and Bronchus | 69.0 | 66.0 | 63.5 | 67.0 | 67.0 | 69.0 | | | | | |
| Breast | 62.0 | 58.0 | 59.5 | 54.0 | 52.0 | 61.0 | | | | | |
| Prostate | 68.0 | 65.0 | 69.5 | 68.0 | 67.0 | 68.0 | | | | | |
| Colorectal | 70.0 | 65.0 | 58.5 | 66.0 | 64.5 | 69.0 | | | | | |
| Urinary Bladder | 72.0 | 68.0 | 60.0 | 68.5 | 65.0 | 71.0 | | | | | |
| Non-Hodgkin's Lymphoma | 67.0 | 58.0 | 68.5 | 57.0 | 55.0 | 66.0 | | | | | |
| Kidney and Renal Pelvis | 65.0 | 61.0 | 70.0 | 58.0 | 60.0 | 64.0 | | | | | |
| Leukemia | 69.0 | 53.0 | | 58.0 | 28.0 | 67.0 | | | | | |
| Lip, Oral Cavity and Pharynx | 63.0 | 62.0 | | 56.0 | 51.5 | 62.0 | | | | | |
| Pancreas | 70.0 | 66.5 | | 65.0 | 62.0 | 69.0 | | | | | |
| Skin | 60.0 | 72.0 | | 43.5 | 46.0 | 60.0 | | | | | |
| Corpus Uteri & Uterus NOS | 63.0 | 64.5 | 48.0 | 52.0 | 56.5 | 61.5 | | | | | |
| Ovary | 65.0 | 70.5 | 55.0 | 55.0 | 52.0 | 63.0 | | | | | |
| Thyroid Gland | 48.0 | 44.0 | | 49.0 | 42.0 | 47.0 | | | | | |
| Stomach Brain and Other Central | 71.0 | 68.0 | | 64.0 | 65.0 | 70.0 | | | | | |
| Nervous System | 59.0 | 48.0 | 0.0 | 47.5 | 35.0 | 57.0 | | | | | |
| Cervix Uteri | 50.0 | 48.0 | | 49.0 | 45.5 | 48.0 | | | | | |
| Liver and Intrahepatic Bile Ducts | 65.5 | 56.5 | | 65.0 | 65.0 | 65.0 | | | | | |
| Esophagus | 68.0 | 68.0 | 0.0 | 65.0 | 68.0 | 68.0 | | | | | |
| Larynx | 66.0 | 64.0 | 0.0 | | 65.0 | 66.0 | | | | | |
| Multiple Myeloma | 69.0 | 67.0 | | 71.0 | 67.0 | 68.0 | | | | | |
| Hodgkin's Lymphoma | 42.0 | 44.0 | | 27.0 | 20.0 | 40.0 | | | | | |
| All Other Sites | 67.0 | 59.0 | 53.0 | 61.5 | 49.0 | 65.0 | | | | | |
| Total | 67.0 | 63.0 | 62.0 | 61.0 | 59.0 | 66.0 | | | | | |

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

HIGHLIGHTS

- Lung And Bronchus Cancer was the leading type of cancer in Nevada from 2000 to 2004. This type of cancer accounted for 13.9% of all resident cancer inpatient hospital discharges during this period. The second leading type, Colorectal Cancer, accounted for 12.7% of all cancer inpatient discharges.
- The two leading types of cancer for inpatient hospital discharges, Colorectal and Lung And Bronchus cancer accounted for 434.2 million dollars in total billed amounts in Nevada from 2000 to 2004. This accounted for 29.7% of the total 1.46 billion dollars in billed amounts for cancer inpatient hospital discharges during this period.
- The five types of cancer that had the highest average total billed amount for Nevada from 2000 to 2004 were: Leukemia (\$88,266), Stomach (\$67,784), Ovary (\$62,375), Larynx (\$60,478), and Non-Hodgkin's Lymphoma (\$56,600) Cancers.
- The five types of cancer that had the highest average length of stay (days) for cancer inpatient hospital discharges in Nevada from 2000 to 2004 were: Leukemia (13.8), Stomach (11.2), Larynx (10.3), Multiple Myeloma (9.8), and Pancreatic (9.5) Cancers.
- The five types of cancer that had the highest average daily billed amount for Nevada from 2000 to 2004 were: Breast (\$7,736), Thyroid Gland (\$7,540), Corpus Uteri & Uterus NOS (\$7,497), Prostate (\$7,370), and Ovary (\$7,234) Cancers.







Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents, 2000-2004










Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital Discharges, Nevada Residents, 2000-2004









Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 2000-2004



| Type of Cancer | Tota | * | Mal | е | Fema | ale |
|---|-----------|--------------|-----------|--------------|-----------|--------|
| Type of cancer | Number | Rate** | Number | Rate** | Number | Rate** |
| Total | 34,796 | 330.00 | 16,799 | 335.00 | 17,994 | 331.00 |
| Lip, Oral Cavity and Pharynx | 526 | 4.80 | 362 | 6.70 | 164 | 3.00 |
| Lip | 8 | | 7 | | 1 | |
| Base of Tongue | 90 | 0.81 | 68 | 1.20 | 22 | 0.40 |
| Other & Unspecified Parts of Tongue | 95 | 0.86 | 62 | 1.10 | 33 | 0.61 |
| Parotid Gland | 46 | 0.44 | 31 | 0.64 | 15 | 0.28 |
| Other & Unspecified Major Salivary glands | 10 | 0.08 | 5 | | 5 | |
| Floor of Mouth | 46 | 0.40 | 35 | 0.61 | 11 | 0.19 |
| Gum | 31 | 0.29 | 18 | 0.33 | 13 | 0.24 |
| Palate | 12 | 0.11 | 4 | | 8 | |
| Other & Unspecified Parts of Mouth | 26 | 0.24 | 17 | 0.31 | 9 | |
| Nasopharynx | 24 | 0.21 | 17 | 0.30 | 7 | |
| Tonsil | 43 | 0.38 | 34 | 0.59 | 9 | |
| Oropharynx | 24 | 0.21 | 19 | 0.34 | 5 | |
| Pyriform Sinus | 16 | 0.15 | 8 | | 8 | |
| Hypopharynx | 25 | 0.22 | 16 | 0.28 | 9 | |
| Other & Unspecified Oral (Buccal) Cavity & Pharynx | 30 | 0.30 | 21 | 0.48 | 9 | |
| Digestive System | 7,018 | 69.00 | 3,831 | 79.00 | 3,187 | 60.00 |
| Esophagus | 302 | 2.90 | 227 | 4.50 | 75 | 1.40 |
| Stomach | 597 | 5.80 | 409 | 8.20 | 188 | 3.60 |
| Small Intestine | 161 | 1.60 | 92 | 1.90 | 69 | 1.30 |
| Colon (excluding Rectum) | 2,966 | 30.00 | 1,455 | 31.00 | 1,511 | 29.00 |
| Cecum | 643 | 6.70 | 309 | 6.70 | 334 | 6.50 |
| Appendix | 34 | 0.31 | 14 | 0.27 | 20 | 0.35 |
| Ascending Colon | 553 | 5.60 | 250 | 5.40 | 303 | 5.80 |
| Hepatic Flexure | 126 | 1.30 | 59 | 1.30 | 67 | 1.30 |
| Transverse Colon | 258 | 2.70 | 107 | 2.20 | 151 | 2.90 |
| Splenic Flexure | 111 | 1.10 | 57 | 1.20 | 54 | 0.99 |
| Descending Colon | 151 | 1.10 | 88 | 1.80 | 63 | 1.20 |
| Sigmoid Colon | 789 | 7.70 | 426 | 8.80 | 363 | 6.80 |
| Large Intestine, NOS | 301 | 3.00 | 145 | 3.20 | 156 | 3.00 |
| Rectum | 726 | 7.00 | 433 | 8.70 | 293 | 5.50 |
| Rectosigmoid Junction | 598 | 5.70 | 337 | 6.80 | 293 | 4.80 |
| Anus, Anal Canal and Anorectum | 143 | 1.40 | 75 | 1.50 | 68 | 4.80 |
| Liver | 336 | 3.20 | 239 | 4.50 | 97 | 1.90 |
| Intrahepatic Bile Ducts | 43 | 0.43 | 239 18 | 4.30 0.36 | 97 25 | 0.48 |
| Gallbladder | 43 29 | 0.43 | 5 | 0.30 | 23 24 | 0.48 |
| | 29 151 | | 85 | | 24 66 | 1.20 |
| Other & Unspecified Biliary Tract | 848 | 1.50 8.30 | 418 | 1.90 8.70 | 430 | 8.00 |
| Pancreas | 040 55 | 8.30 0.51 | 418 29 | 0.70 0.57 | 430 26 | 0.47 |
| Retroperitoneum | 55 54 | | 29 5 | 0.57 | | |
| Peritoneum, Omentum and Mesentery | | 0.50 | | | 49 | 0.89 |
| Other Digestive Organs | 9 | | 4 | | 5 | 45.00 |
| Respiratory System | 5,155 | 49.00 | 2,673 | 54.00 | 2,482 | 45.00 |
| Nasal Cavity and Middle Ear | 10 | 0.11 | 5 | | 5 | |
| Accessory Sinuses | 19 | 0.18 | 11 | 0.20 | 8 | |
| Larynx | 166 | 1.60 | 125 | 2.50 | 41 | 0.77 |
| Lung and Bronchus | 4,842 | 46.00 | 2,463 | 49.00 | 2,379 | 43.00 |
| Pleura | 57 | 0.55 | 38 | 0.78 | 19 | 0.35 |
| Trachea | 12 | 0.11 | 7 | | 5 | |
| Mediastinum and Other Respiratory Organs | 49 | 0.46 | 24 | 0.50 | 25 | 0.44 |
| Bones, Joints and Articular Cartilage | 121 | 1.10 | 66 | 1.30 | 55 | 1.00 |
| Bones, Joints & Articular Cartilage of Limbs | 53 | 0.48 | 19 | 0.33 | 34 | 0.64 |
| Bones, Joints & Articular Cartilage of Other & Unspec Sites | 68 | 0.66 | 47 | 0.94 | 21 | 0.39 |
| Soft Tissue (Including Heart) | 175 | 1.70 | 86 | 1.70 | 89 | 1.70 |
| Heart | 4 | | 1 | | 3 | |
| Peripheral Nerves & Autonomic Nervous System | 0 | | 0 | | 0 | |
| Connective, Subcutaneous & Other Soft Tissues | 171 | 1.60 | 85 | 1.70 | 86 | 1.60 |

Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 2000-2004

* Those of unknown gender are not shown separately, but are included in the total.
 ** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.
 Note: The "---" is used for rates calculated on numbers less than ten.

| 7 | Tota | * | Mal | e | Female | |
|---|--------|--------|--------|--------|--------|--------|
| Type of Cancer | Number | Rate** | Number | Rate** | Number | Rate** |
| Total | 34,796 | 330.00 | 16,799 | 335.00 | 17,994 | 331.00 |
| Skin (Excluding Basal And Squamous) | 206 | 2.00 | 143 | 2.90 | 63 | 1.20 |
| Melanomas Of The Skin | 93 | 0.86 | 63 | 1.20 | 30 | 0.56 |
| Other Non-Epithelial Skin | 113 | 1.10 | 80 | 1.80 | 33 | 0.63 |
| Breast | 2,276 | 22.00 | 23 | 0.52 | 2,253 | 41.00 |
| Female Genital System | 2,488 | 23.00 | 0 | | 2,488 | 45.00 |
| Cervix Uteri | 609 | 5.50 | 0 | | 609 | 11.00 |
| Corpus Uteri | 915 | 8.50 | 0 | | 915 | 17.00 |
| Uterus, NOS | 31 | 0.30 | 0 | | 31 | 0.58 |
| Ovary | 721 | 6.70 | 0 | | 721 | 13.00 |
| Vagina | 37 | 0.37 | 0 | | 37 | 0.70 |
| Vulva | 129 | 1.30 | 0 | | 129 | 2.40 |
| Placenta | 3 | | 0 | | 3 | |
| Other Female Genital Organs | 43 | 0.39 | 0 | | 43 | 0.77 |
| Male Genital System | 2,682 | 24.00 | 2,682 | 51.00 | 0 | |
| Prostate | 2,614 | 24.00 | 2,614 | 50.00 | 0 | |
| Testis | 51 | 0.45 | 51 | 0.87 | 0 | |
| Penis | 15 | 0.16 | 15 | 0.37 | 0 | |
| Other Male Genital Organs | 2 | | 2 | | 0 | |
| Urinary System | 2,191 | 21.00 | 1,550 | 32.00 | 641 | 12.00 |
| Urinary Bladder | 1,033 | 11.00 | 803 | 18.00 | 230 | 4.40 |
| Kidney | 986 | 9.10 | 638 | 12.00 | 348 | 6.30 |
| Renal Pelvis | 84 | 0.82 | 56 | 1.20 | 28 | 0.51 |
| Ureter | 71 | 0.70 | 45 | 0.94 | 26 | 0.49 |
| Other Urinary Organs | 17 | 0.16 | 8 | | 9 | |
| Eye and Orbit | 9 | | 3 | | 6 | |
| Brain and Other Central Nervous System | 946 | 8.80 | 524 | 9.80 | 422 | 7.80 |
| Brain | 874 | 8.10 | 494 | 9.30 | 380 | 7.00 |
| Meninges | 47 | 0.44 | 19 | 0.37 | 28 | 0.52 |
| Spinal Cord, Cranial Nerves, & Other Parts of CNS | 25 | 0.23 | 11 | 0.20 | 14 | 0.26 |
| Endocrine System | 1,617 | 15.00 | 353 | 6.50 | 1,264 | 23.00 |
| Thyroid Gland | 1,570 | 14.00 | 332 | 6.00 | 1,238 | 23.00 |
| Adrenal Gland | 19 | 0.18 | 9 | | 10 | 0.18 |
| Other Endocrine (Including Thymus) | 28 | 0.28 | 12 | 0.29 | 16 | 0.29 |
| Hodgkin's Lymphoma | 118 | 1.10 | 63 | 1.10 | 54 | 0.97 |
| Non-Hodgkin's Lymphoma | 1,055 | 10.00 | 583 | 12.00 | 472 | 8.90 |
| Multiple Myeloma | 373 | 3.60 | 213 | 4.30 | 160 | 2.90 |
| Leukemia | 1,041 | 10.00 | 597 | 12.00 | 443 | 8.40 |
| Lymphocytic | 442 | 4.20 | 257 | 5.00 | 184 | 3.50 |
| Acute Lymphocytic | 302 | 2.80 | 177 | 3.20 | 124 | 2.30 |
| Chronic Lymphocytic | 136 | 1.40 | 77 | 1.70 | 59 | 1.10 |
| Other Lymphocytic | 4 | | 3 | | 1 | |
| Myeloid and Monocytic | 552 | 5.30 | 314 | 6.30 | 238 | 4.50 |
| Acute Myeloid | 443 | 4.30 | 252 | 5.10 | 191 | 3.60 |
| Acute Monocytic | 10 | 0.11 | 2 | | 8 | |
| Chronic Myeloid | 92 | 0.92 | 57 | 1.20 | 35 | 0.69 |
| Other Myeloid/Monocytic | 7 | | 3 | | 4 | |
| Other | 47 | 0.47 | 26 | 0.55 | 21 | 0.41 |
| Other Acute | 33 | 0.33 | 18 | 0.40 | 15 | 0.28 |
| Aleukemic, Subleukemic and NOS | 14 | 0.14 | 8 | | 6 | |
| Mesothelioma | 1 | | 1 | | 0 | |
| Kaposi Sarcoma | 0 | | 0 | | 0 | |
| Other, III-Defined and Unspecified Sites | 6,798 | 64.00 | 3,046 | 61.00 | 3,751 | 68.00 |

Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender,
Nevada, 2000-2004 (Continued)

* Those of unknown gender are not shown separately, but are included in the total.

** Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 genderspecific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by
County/Region of Residence, Nevada Residents, 2000-2004

| | | | | County/Region | n of Residence | |
|------|---------------------------|------------|-----------------|---------------|----------------|-----------------------|
| Rank | Type of Cance | ər | Nevada Total | Clark | Washoe | All Other Counties |
| 1 | Lung And Bronchus | Admissions | 4,842 | 3,449 | 738 | 653 |
| | | Rate* | 45.98 | 47.80 | 45.18 | 39.02 |
| | | 95% C.I. | (44.7-47.3) | (46.2-49.5) | (41.9-48.6) | (36.1-42.2) |
| 2 | Colorectal | Admissions | 4,433 | 3,098 | 717 | 617 |
| | | Rate* | 44.10 | 44.96 | 45.55 | 38.54 |
| | | 95% C.I. | (42.8-45.5) | (43.3-46.6) | (42.2-49.1) | (35.5-41.8) |
| 3 | Prostate | Admissions | 2,614 | 1,696 | 493 | 425 |
| | | Rate* | 23.80 | 22.61 | 28.32 | 24.53 |
| | | 95% C.I. | (22.9-24.7) | (21.5-23.7) | (25.8-31.0) | (22.2-27.0) |
| 4 | Breast | Admissions | 2,276 | 1,654 | 362 | 260 |
| | | Rate* | 21.51 | 22.72 | 21.43 | 16.06 |
| | | 95% C.I. | (20.6-22.4) | (21.6-23.9) | (19.2-23.8) | (14.1-18.2) |
| 5 | Thyroid Gland | Admissions | 1,570 | 1,312 | 196 | 145 |
| | | Rate* | 14.10 | 16.90 | 11.79 | 8.75 |
| | | 95% C.I. | (13.4-14.8) | (16.0-17.9) | (10.2-13.6) | (7.4-10.3) |
| 6 | Kidney And Renal Pelvis | Admissions | 1,070 | 780 | 176 | 141 |
| | | Rate* | 9.92 | 10.77 | 10.25 | 8.83 |
| | | 95% C.I. | (9.3-10.5) | (10.0-11.6) | (8.8-11.9) | (7.4-10.5) |
| 7 | Non-Hodgkins Lymphoma | Admissions | 1,055 | 749 | 161 | 140 |
| | | Rate* | 10.20 | 10.14 | 9.51 | 8.75 |
| | | 95% C.I. | (9.6-10.9) | (9.4-10.9) | (8.1-11.1) | (7.3-10.4) |
| 8 | Leukemia | Admissions | 1,041 | 746 | 161 | 133 |
| | | Rate* | 10.02 | 11.16 | 8.75 | 8.09 |
| | | 95% C.I. | (9.4-10.7) | (10.4-12.0) | (7.4-10.2) | (6.8-9.6) |
| 9 | Urinary Bladder | Admissions | 1,033 | 736 | 158 | 131 |
| | | Rate* | 10.52 | 10.30 | 9.75 | 8.49 |
| | | 95% C.I. | (9.9-11.2) | (9.6-11.1) | (8.3-11.5) | (7.1-10.1) |
| 10 | Corpus Uteri & Uterus Nos | Admissions | 946 | 676 | 145 | 122 |
| | | Rate* | 8.84 | 9.07 | 8.50 | 7.86 |
| | | 95% C.I. | (8.3-9.4) | (8.4-9.8) | (7.2-10.1) | (6.5-9.4) |
| | Total | Admissions | 34,796 | 24,777 | 5,576 | 4,431 |
| | | Rate* | 330.42 | 341.87 | 335.05 | 272.11 |
| | | 95% C.I. | (326.9-334.0) | (337.5-346.2) | (326.2-344.1) | (264.0-280.8) |
| | | | , | , | , | . , |

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residents, 2000-2004

| Ranking | | | | | Age Group | | | | |
|-----------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Kalikilig | 0-14 | 15-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 | 75+ | Total |
| 1 | Leukemia | Thyroid Gland | Thyroid Gland | Thyroid Gland | Colorectal | Lung & Bronchus | Lung & Bronchus | Colorectal | Lung & Bronchus |
| | 205 | 77 | 259 | 394 | 493 | 1,268 | 1,695 | 1,514 | 4,842 |
| | 44.3% | 20.4% | 28.7% | 18.4% | 9.8% | 14.9% | 17.8% | 19.3% | 13.9% |
| 2 | Brain and OCNS | Leukemia | Leukemia | Breast | Breast | Prostate | Colorectal | Lung & Bronchus | Colorectal |
| | 68 | 55 | 66 | 232 | 487 | 1,019 | 1,310 | 1,313 | 4,433 |
| | 14.7% | 14.6% | 7.3% | 10.8% | 9.7% | 12.0% | 13.8% | 16.7% | 12.7% |
| 3 | NHL | Brain and OCNS | Cervix Uteri | Cervix Uteri | Lung & Bronchus | Colorectal | Prostate | Urinary Bladder | Prostate |
| | 26 | 37 | 62 | 164 | 457 | 929 | 905 | 464 | 2,614 |
| | 5.6% | 9.8% | 6.9% | 7.7% | 9.1% | 10.9% | 9.5% | 5.9% | 7.5% |
| 4 | Liver and IBD | NHL | Brain and OCNS | Colorectal | Thyroid Gland | Breast | Breast | Breast | Breast |
| | 24 | 31 | 62 | 145 | 373 | 543 | 535 | 433 | 2,276 |
| | 5.2% | 8.2% | 6.9% | 6.8% | 7.4% | 6.4% | 5.6% | 5.5% | 6.5% |
| 5 | KRP | HL | NHL | Brain and OCNS | Prostate | KRP | Urinary Bladder | Prostate | Thyroid Gland |
| | 20 | 18 | 44 | 106 | 321 | 305 | 307 | 354 | 1,570 |
| | 4.3% | 4.8% | 4.9% | 5.0% | 6.4% | 3.6% | 3.2% | 4.5% | 4.5% |
| 6 | HL | Ovary | Breast | Lung & Bronchus | Brain and OCNS | Thyroid Gland | KRP | NHL | KRP |
| | 15 | 12 | 41 | 95 | 179 | 273 | 303 | 268 | 1,070 |
| | 3.2% | 3.2% | 4.6% | 4.4% | 3.6% | 3.2% | 3.2% | 3.4% | 3.1% |
| 7 | Thyroid Gland | Stomach | Ovary | CU & Uterus NOS | KRP | CU & Uterus NOS | NHL | Pancreas | NHL |
| | 5 | 8 | 37 | 79 | 173 | 263 | 257 | 246 | 1,055 |
| | 1.1% | 2.1% | 4.1% | 3.7% | 3.5% | 3.1% | 2.7% | 3.1% | 3.0% |
| 8 | LOCP | Colorectal | Colorectal | NHL | CU & Uterus NOS | Pancreas | Pancreas | Leukemia | Leukemia |
| | 3 | 8 | 33 | 77 | 172 | 211 | 255 | 218 | 1,041 |
| | 0.6% | 2.1% | 3.7% | 3.6% | 3.4% | 2.5% | 2.7% | 2.8% | 3.0% |
| 9 | Ovary | Lung & Bronchus | HL | KRP | Cervix Uteri | NHL | CU & Uterus NOS | KRP | Urinary Bladder |
| | 3 | 6 | 22 | 66 | 159 | 199 | 237 | 193 | 1,033 |
| | 0.6% | 1.6% | 2.4% | 3.1% | 3.2% | 2.3% | 2.5% | 2.5% | 3.0% |
| 10 | Breast | Liver and IBD | CU & Uterus NOS | Leukemia | NHL | Brain and OCNS | Leukemia | CU & Uterus NOS | CU & Uterus NOS |
| | 2 | 4 | 16 | 59 | 153 | 194 | 192 | 179 | 946 |
| | 0.4% | 1.1% | 1.8% | 2.8% | 3.1% | 2.3% | 2.0% | 2.3% | 2.7% |
| Sum | 371 | 256 | 642 | 1,417 | 2,967 | 5,204 | 5,996 | 5,182 | 20,880 |
| Percent | 80.1% | 67.7% | 71.3% | 66.2% | 59.2% | 61.0% | 63.0% | 65.9% | 60.0% |
| Total | 463 | 378 | 901 | 2,141 | 5,014 | 8,525 | 9,513 | 7,861 | 34,796 |
| | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

MORTALITY <u>HIGHLIGHTS</u>

- Lung And Bronchus Cancer was the leading type of cancer for cancer mortality in Nevada from 2000 to 2004. This type of cancer accounted for 31.0% of all resident cancer deaths during this period. The second leading type of cancer for cancer mortality, Colorectal Cancer, accounted for 10.5% of all Cancer deaths.
- Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer mortality rates for Whites, with a ratio of 1.06. This means that for every 100 White cancer deaths Blacks would be expected to have 106 deaths. Asians, Hispanics and Native Americans had comparison ratios of 0.57, 0.55 and 0.48, respectively, for Nevada from 2000 to 2004.
- Stomach cancer had the highest age-adjusted mortality comparison ratio for Blacks when compared to Whites in Nevada from 2000 to 2004 with a comparison ratio of 2.27. This means that for every 100 White Stomach cancer deaths Blacks would be expected to have 227. Liver and Intrahepatic Bile Ducts cancer had the highest age-adjusted comparison ratio for Asians when compared to Whites in Nevada from 2000 to 2004 at 2.07.
- Cervix Uteri had the lowest median age at time of death for Nevada residents from 2000 to 2004 at 58 years. Prostate Cancer had the highest median age at time of death for Nevada residents during this same period at 78 years.
- Hodgkin's Lymphoma had the lowest median age at time of death for male Nevada residents from 2000 to 2004 at 56.5 years, while the highest median age was Prostate Cancer at 78 years.
- Cervix Uteri had the lowest median age at time of death for male Nevada residents from 2000 to 2004 at 58 years, while the highest median age was Urinary Bladder Cancer at 76 years.






Figure 16. Comparison of Age-Adjusted (2000) Mortality Rates of Blacks compared to Whites, Nevada Residents, 2000-2004






Figure 17. Comparison of Age-Adjusted (2000) Mortality Rates of Native Americans compared to Whites, Nevada Residents, 2000-2004




Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 18. Comparison of Age-Adjusted (2000) Mortality Rates of Asians compared to Whites, Nevada Residents, 2000-2004



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 19. Comparison of Age-Adjusted (2000) Mortality Rates of Hispanics compared to Whites, Nevada Residents, 2000-2004



Note: "N/A" indicates that a comparison ratio could not be calculated.

| Time of Orman | Total | * | Mal | е | Fema | Female | |
|---|----------|----------|---------|----------|---------|----------|--|
| Type of Cancer | Number | Rate** | Number | Rate** | Number | Rate** | |
| Total | 19,379 | 197.00 | 10,396 | 231.00 | 8,983 | 170.00 | |
| Lip, Oral Cavity and Pharynx | 296 | 2.90 | 209 | 4.30 | 87 | 1.70 | |
| Lip | 2 | | 1 | | 1 | | |
| Base of Tongue | 3 | | 3 | | 0 | | |
| Other & Unspecified Parts of Tongue | 77 | 0.71 | 58 | 1.10 | 19 | 0.35 | |
| Parotid Gland | 15 | 0.15 | 10 | 0.22 | 5 | | |
| Other & Unspecified Major Salivary glands | 3 | | 3 | | 0 | | |
| Floor of Mouth | 3 | | 3 | | 0 | | |
| Gum | 4 | | 2 | | 2 | | |
| Palate | 6 | | 2 | | 4 | | |
| Other & Unspecified Parts of Mouth | 26 | 0.26 | 15 | 0.34 | 11 | 0.21 | |
| Nasopharynx | 28 | 0.25 | 21 | 0.38 | 7 | | |
| Tonsil | 19 | 0.18 | 12 | 0.24 | 7 | | |
| Oropharynx | 20 | 0.19 | 15 | 0.29 | 5 | | |
| Pyriform Sinus | 1 | | 1 | | 0 | | |
| Hypopharynx | 3 | | 3 | | 0 | | |
| Other & Unspecified Oral (Buccal) Cavity & Pharynx | 86 | 0.86 | 60 | 1.30 | 26 | 0.49 | |
| Digestive System | 4,527 | 46.00 | 2,666 | 58.00 | 1,861 | 36.00 | |
| Esophagus | 459 | 4.40 | 368 | 7.40 | 91 | 1.70 | |
| Stomach | 346 | 3.60 | 221 | 4.90 | 125 | 2.50 | |
| Small Intestine | 34 | 0.35 | 16 | 0.37 | 18 | 0.34 | |
| Colon (excluding Rectum) | 1,718 | 18.00 | 934 | 22.00 | 784 | 15.00 | |
| Cecum | 10 | 0.13 | 5 | | 5 | | |
| Appendix | 4 | | 3 | | 1 | | |
| Ascending Colon | 3 | | 3 | | 0 | | |
| Hepatic Flexure | 0 | | 0 | | 0 | | |
| Transverse Colon | 1 | | 0 | | 1 | | |
| Splenic Flexure | 0 | | 0 | | 0 | | |
| Descending Colon | 0 | | 0 | | 0 | | |
| Sigmoid Colon | 10 | 0.10 | 5 | | 5 | | |
| Large Intestine, NOS | 1,690 | 18.00 | 918 | 21.00 | 772 | 15.00 | |
| Rectum | 205 | 2.10 | 126 | 2.90 | 79 | 1.50 | |
| Rectosigmoid Junction | 86 | 0.87 | 50 | 1.00 | 36 | 0.70 | |
| Anus, Anal Canal and Anorectum | 21 | 0.20 | 10 | 0.20 | 11 | 0.19 | |
| Liver | 419 | 4.10 | 294 | 5.90 | 125 | 2.40 | |
| Intrahepatic Bile Ducts | 82 | 0.81 | 54 | 1.10 | 28 | 0.52 | |
| Gallbladder | 39 | 0.41 | 17 | 0.46 | 22 | 0.41 | |
| Other & Unspecified Biliary Tract | 51 | 0.53 | 25 | 0.58 | 26 | 0.50 | |
| Pancreas | 1,017 | 10.00 | 529 | 11.00 | 488 | 9.30 | |
| Retroperitoneum | 4 | | 3 | | 1 | | |
| Peritoneum, Omentum and Mesentery | 15 | 0.16 | 4 | | 11 | 0.21 | |
| Other Digestive Organs | 31 | 0.31 | 15 | 0.29 | 16 | 0.30 | |
| Respiratory System | 6,138 | 61.00 | 3,338 | 71.00 | 2,800 | 52.00 | |
| Nasal Cavity and Middle Ear | 0 | | 0 | | 0 | | |
| Accessory Sinuses | 13 | 0.13 | 7 | | 6 | | |
| Larynx | 108 | 1.10 | 78 | 1.60 | 30 | 0.57 | |
| Lung and Bronchus | 6,005 | 59.00 | 3,244 | 69.00 | 2,761 | 52.00 | |
| Pleura | 3 | | 2 | | 1 | | |
| Trachea | 2 | | 2 | | 0 | | |
| Mediastinum and Other Respiratory Organs | 7 | | 5 | | 2 | | |
| Bones, Joints and Articular Cartilage | 49 | 0.50 | 29 | 0.62 | 20 | 0.39 | |
| Bones, Joints & Articular Cartilage of Limbs | 1 | | 0 | | 1 | | |
| Bones, Joints & Articular Cartilage of Other & Unspec Sites | 48 | 0.49 | 29 | 0.62 | 19 | 0.37 | |
| Soft Tissue (Including Heart) | 122 | 1.20 | 61 | 1.20 | 61 | 1.10 | |
| Heart Porisharal Nanas & Autonomia Nanaus Sustam | 3 | | 2 | | 1 | | |
| Peripheral Nerves & Autonomic Nervous System Connective, Subcutaneous & Other Soft Tissues | 2 117 | 1.10 | 1 58 | 1.20 | 1 59 | 1.10 | |

Table 14. Nevada Mortality by Type of Cancer and Gender,
Nevada, 2000-2004

* Those of unknown gender are not shown separately, but are included in the total.

**Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

| | Total | * | Mal | e | Fema | ale |
|--|----------|--------------|-----------|--------------|-----------|--------------|
| Type of Cancer | Number | Rate** | Number | Rate** | Number | Rate** |
| Total | 19,379 | 197.00 | 10,396 | 231.00 | 8,983 | 170.00 |
| Skin (Excluding Basal And Squamous) | 378 | 3.70 | 263 | 5.40 | 115 | 2.20 |
| Melanomas Of The Skin | 298 | 2.80 | 201 | 4.00 | 97 | 1.80 |
| Other Non-Epithelial Skin | 80 | 0.83 | 62 | 1.40 | 18 | 0.36 |
| Breast | 1,357 | 14.00 | 15 | 0.30 | 1,342 | 25.00 |
| Female Genital System | 803 | 8.00 | 2 | | 801 | 15.00 |
| Cervix Uteri | 149 | 1.40 | 0 | | 149 | 2.80 |
| Corpus Uteri | 60 | 0.62 | 1 | | 59 | 1.10 |
| Uterus, NOS | 96 | 1.00 | 0 | | 96 | 1.90 |
| Ovary | 457 | 4.50 | 1 | | 456 | 8.50 |
| Vagina | 10 | 0.10 | 0 | | 10 | 0.19 |
| Vulva | 18 | 0.19 | 0 | | 18 | 0.35 |
| Placenta | 0 | | 0 | | 0 | |
| Other Female Genital Organs | 13 | 0.15 | 0 | | 13 | 0.26 |
| Male Genital System | 1,016 | 12.00 | 1,016 | 28.00 | 0 | |
| Prostate | 995 | 11.00 | 995 | 27.00 | 0 | |
| Testis | 15 | 0.14 | 15 | 0.30 | 0 | |
| Penis | 4 | | 4 | | 0 | |
| Other Male Genital Organs | 2 | | 2 | | 0 | |
| Urinary System | 902 | 9.30 | 623 | 14.00 | 279 | 5.40 |
| Urinary Bladder | 474 | 5.10 | 339 | 8.50 | 135 | 2.70 |
| Kidney | 396 | 3.90 | 263 | 5.60 | 133 | 2.50 |
| Renal Pelvis | 4 | | 2 | | 2 | |
| Ureter | 11 | 0.10 | 6 | | 5 | |
| Other Urinary Organs | 17 | 0.17 | 13 | 0.31 | 4 | |
| Eye and Orbit | 8 | | 7 | | 1 | |
| Brain and Other Central Nervous System | 415 | 4.00 | 240 | 4.70 | 175 | 3.30 |
| Brain | 409 | 3.90 | 236 | 4.60 | 173 | 3.20 |
| Meninges | 2 | | 2 | | 0 | |
| Spinal Cord, Cranial Nerves, & Other Parts of CNS | 4 | | 2 | | 2 | |
| Endocrine System | 53 | 0.53 | 30 | 0.66 | 23 | 0.43 |
| Thyroid Gland | 29 | 0.29 | 18 | 0.39 | 11 | 0.20 |
| Adrenal Gland | 14 | 0.14 | 7 | | 7 | |
| Other Endocrine (Including Thymus) Hodgkin's Lymphoma | 10 37 | 0.10 | 5 | | 5 | |
| Non-Hodgkin's Lymphoma | 630 | 0.35 6.60 | 20 357 | 0.36 8.20 | 17 273 | 0.33 5.30 |
| Multiple Myeloma | 341 | 3.40 | 201 | 4.40 | 140 | 2.70 |
| Leukemia | 699 | 7.30 | 421 | 9.50 | 278 | 5.40 |
| Lymphocytic | 184 | 2.00 | 115 | 2.70 | 69 | 1.40 |
| Acute Lymphocytic | 44 | 0.44 | 29 | 0.62 | 15 | 0.28 |
| Chronic Lymphocytic | 128 | 1.40 | 78 | 1.90 | 50 | 1.00 |
| Other Lymphocytic | 12 | 0.13 | 8 | | 4 | |
| Myeloid and Monocytic | 295 | 3.00 | 176 | 3.80 | 119 | 2.30 |
| Acute Myeloid | 200 | 2.30 | 131 | 2.80 | 96 | 1.80 |
| Acute Monocytic | 2 | | 1 | | 1 | |
| Chronic Myeloid | 47 | 0.47 | 28 | 0.57 | 19 | 0.37 |
| Other Myeloid/Monocytic | 19 | 0.20 | 16 | 0.37 | 3 | 0.57 |
| Other | 220 | 2.30 | 130 | 3.00 | 90 | 1.80 |
| Other Acute | 84 | 0.84 | 53 | 1.20 | 30 | 0.58 |
| Aleukemic, Subleukemic and NOS | 136 | 1.50 | 55 77 | 1.80 | 59 | 1.20 |
| Mesothelioma | 73 | 0.72 | 56 | 1.20 | 17 | 0.31 |
| Kaposi Sarcoma | 0 | | 0 | | 0 | |
| Other, III-Defined and Unspecified Sites | 1,535 | 16.00 | 842 | 19.00 | 693 | 13.00 |

Table 14. Nevada Mortality by Type of Cancer and Gender,
Nevada, 2000-2004 (Continued)

* Those of unknown gender are not shown separately, but are included in the total.

**Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence,
Nevada Residents, 2000-2004

| | | | | County/Region | n of Residence | |
|------|--------------------------------|----------------|-----------------|---------------|----------------|-----------------------|
| Rank | Type of Cano | cer | Nevada Total | Clark | Washoe | All Other Counties |
| 1 | Lung And Bronchus | Mortality | 6,005 | 4,066 | 943 | 996 |
| | | Rate* | 59.26 | 59.03 | 59.34 | 60.69 |
| | | 95% C.I. | (57.7-60.8) | (57.2-60.9) | (55.6-63.3) | (56.9-64.7) |
| 2 | Colorectal | Mortality | 2,030 | 1,422 | 322 | 286 |
| | | Rate* | 21.37 | 21.96 | 21.28 | 18.88 |
| | | 95% C.I. | (20.4-22.4) | (20.8-23.2) | (19.0-23.8) | (16.7-21.3) |
| 3 | Breast | Mortality | 1,357 | 943 | 238 | 185 |
| | | Rate* | 13.60 | 13.90 | 14.83 | 12.89 |
| | | 95% C.I. | (12.9-14.4) | (13.0-14.9) | (13.0-16.9) | (11.1-15.0) |
| 4 | Pancreas | Mortality | 1,017 | 693 | 173 | 176 |
| | | Rate* | 10.23 | 10.07 | 12.38 | 11.00 |
| | | 95% C.I. | (9.6-10.9) | (9.3-10.9) | (10.6-14.4) | (9.4-12.8) |
| 5 | Prostate | Mortality | 995 | 637 | 160 | 164 |
| | | Rate* | 11.37 | 10.72 | 10.37 | 10.51 |
| | | 95% C.I. | (10.7-12.1) | (9.9-11.6) | (8.8-12.2) | (8.9-12.3) |
| 6 | Leukemia | Mortality | 699 | 471 | 112 | 116 |
| | | Rate* | 7.31 | 7.20 | 7.43 | 8.11 |
| | | 95% C.I. | (6.8-7.9) | (6.5-7.9) | (6.1-9.0) | (6.4-10.6) |
| 7 | Non-Hodgkin's Lymphoma | Mortality | 630 | 415 | 109 | 106 |
| | | Rate* | 6.57 | 6.32 | 7.07 | 7.08 |
| | | 95% C.I. | (6.0-7.1) | (5.7-7.0) | (5.8-8.6) | (5.8-8.6) |
| 8 | Liver And Intrahepatic Bile Du | uct: Mortality | 501 | 352 | 80 | 78 |
| | | Rate* | 4.95 | 5.06 | 4.96 | 4.75 |
| | | 95% C.I. | (4.5-5.4) | (4.5-5.6) | (3.9-6.2) | (3.7-6.0) |
| 9 | Urinary Bladder | Mortality | 474 | 327 | 77 | 78 |
| | | Rate* | 5.13 | 4.60 | 4.95 | 5.18 |
| | | 95% C.I. | (4.7-5.6) | (4.1-5.1) | (3.9-6.2) | (4.1-6.5) |
| 10 | Esophagus | Mortality | 459 | 322 | 75 | 75 |
| | | Rate* | 4.43 | 4.61 | 5.05 | 4.75 |
| | | 95% C.I. | (4.0-4.9) | (4.1-5.2) | (4.0-6.4) | (3.7-6.0) |
| | Total | Mortality | 19,379 | 13,190 | 3,105 | 3,084 |
| | | Rate* | 196.53 | 195.98 | 199.37 | 196.35 |
| | | 95% C.I. | (193.7-199.4) | (192.5-199.5) | (192.3-206.7) | (189.3-204.0) |
| | | | (·····/ | (| , | (|

* Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 2000-2004

| Ranking | | | | | Age Group | | | | |
|---------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Kanking | 0-14 | 15-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 | 75+ | Total |
| 1 | Leukemia | Brain and OCNS | Leukemia | Breast | Lung & Bronchus |
| | 19 | 11 | 19 | 89 | 418 | 1,271 | 2,135 | 2,103 | 6,003 |
| | 43.2% | 20.0% | 14.3% | 18.0% | 24.9% | 33.6% | 37.0% | 28.3% | 31.0% |
| 2 | Brain and OCNS | Leukemia | Brain and OCNS | Lung & Bronchus | Breast | Colorectal | Colorectal | Colorectal | Colorectal |
| | 12 | 10 | 13 | 69 | 213 | 330 | 576 | 917 | 2,030 |
| | 27.3% | 18.2% | 9.8% | 13.9% | 12.7% | 8.7% | 10.0% | 12.4% | 10.5% |
| 3 | Liver and IBD | NHL | Breast | Colorectal | Colorectal | Breast | Breast | Prostate | Breast |
| | 4 | 5 | 9 | 46 | 154 | 307 | 317 | 627 | 1,356 |
| | 9.1% | 9.1% | 6.8% | 9.3% | 9.2% | 8.1% | 5.5% | 8.5% | 7.0% |
| 4 | KRP | Liver and IBD | Cervix Uteri | Skin | Pancreas | Pancreas | Pancreas | Breast | Pancreas |
| | 1 | 3 | 9 | 31 | 86 | 210 | 307 | 421 | 1,017 |
| | 2.3% | 5.5% | 6.8% | 6.3% | 5.1% | 5.5% | 5.3% | 5.7% | 5.2% |
| 5 | NHL | Skin | Colorectal | Brain and OCNS | Liver and IBD | Esophagus | Prostate | Pancreas | Prostate |
| | 1 | 3 | 7 | 29 | 84 | 130 | 271 | 394 | 995 |
| | 2.3% | 5.5% | 5.3% | 5.9% | 5.0% | 3.4% | 4.7% | 5.3% | 5.1% |
| 6 | LOCP | Stomach | Skin | Cervix Uteri | Skin | KRP | NHL | Leukemia | Leukemia |
| | 0 | 2 | 7 | 24 | 58 | 113 | 177 | 304 | 699 |
| | 0.0% | 3.6% | 5.3% | 4.8% | 3.5% | 3.0% | 3.1% | 4.1% | 3.6% |
| 7 | Esophagus | LOCP | Lung & Bronchus | NHL | Brain and OCNS | NHL | Leukemia | NHL | NHL |
| | 0 | 1 | 6 | 24 | 58 | 107 | 175 | 273 | 630 |
| | 0.0% | 1.8% | 4.5% | 4.8% | 3.5% | 2.8% | 3.0% | 3.7% | 3.3% |
| 8 | Stomach | Pancreas | Stomach | Leukemia | Ovary | Ovary | Liver and IBD | Urinary Bladder | Liver and IBD |
| | 0 | 1 | 5 | 23 | 52 | 106 | 152 | 253 | 501 |
| | 0.0% | 1.8% | 3.8% | 4.6% | 3.1% | 2.8% | 2.6% | 3.4% | 2.6% |
| 9 | Colorectal | Lung & Bronchus | NHL | Ovary | Leukemia | Leukemia | Esophagus | Liver and IBD | Urinary Bladder |
| | 0 | 1 | 5 | 17 | 48 | 101 | 135 | 156 | 474 |
| | 0.0% | 1.8% | 3.8% | 3.4% | 2.9% | 2.7% | 2.3% | 2.1% | 2.4% |
| 10 | Pancreas | HL | Liver and IBD | Liver and IBD | Esophagus | Brain and OCNS | Ovary | Ovary | Esophagus |
| | 0 | 1 | 3 | 16 | 45 | 90 | 128 | 152 | 459 |
| | 0.0% | 1.8% | 2.3% | 3.2% | 2.7% | 2.4% | 2.2% | 2.0% | 2.4% |
| Sum | 37 | 38 | 83 | 368 | 1,216 | 2,765 | 4,373 | 5,600 | 14,164 |
| Percent | 84.1% | 69.1% | 62.4% | 74.3% | 72.4% | 73.0% | 75.9% | 75.5% | 73.1% |
| Total | 44 | 55 | 133 | 495 | 1,680 | 3,786 | 5,764 | 7,419 | 19,376 |
| | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.


Table 17. Median Age at Time of Death by Leading Types of Cancer and
Race/Ethnicity, Nevada Residents, 2000-2004

| | | | Race/E | thnicity | | |
|---|-------|-------|--------------------|----------|----------|-------|
| Type of Cancer | White | Black | Native American | Asian | Hispanic | Total |
| Lung and Bronchus | 71.0 | 67.0 | 69.0 | 67.0 | 70.0 | 70.0 |
| Breast | 68.0 | 62.0 | 60.0 | 57.0 | 57.0 | 67.0 |
| Prostate | 78.0 | 74.5 | | 77.0 | 78.5 | 78.0 |
| Colorectal | 73.0 | 69.0 | 58.0 | 67.0 | 72.0 | 73.0 |
| Urinary Bladder | 76.0 | 73.0 | | 67.0 | 80.5 | 76.0 |
| Non-Hodgkin's Lymphoma | 73.0 | 67.0 | | 71.0 | 70.0 | 73.0 |
| Kidney and Renal Pelvis | 69.0 | 64.0 | 69.5 | 71.0 | 60.5 | 68.0 |
| Leukemia | 73.0 | 62.5 | | 66.5 | 60.0 | 72.0 |
| Lip, Oral Cavity and Pharynx | 70.0 | 64.0 | | 53.5 | 63.0 | 69.0 |
| Pancreas | 72.0 | 68.0 | | 68.0 | 66.0 | 71.0 |
| Skin | 63.0 | | | | | 63.0 |
| Corpus Uteri & Uterus NOS | 72.0 | 65.5 | | 56.5 | 64.0 | 71.0 |
| Ovary | 70.0 | 65.0 | | 62.0 | 60.0 | 68.0 |
| Thyroid Gland | 73.0 | | | | | 72.0 |
| Stomach Brain and Other Central | 73.0 | 70.5 | | 68.0 | 63.0 | 72.0 |
| Nervous System | 65.0 | 66.0 | | 53.0 | 49.0 | 64.0 |
| Cervix Uteri Liver and Intrahepatic Bile | 59.0 | 50.0 | | 55.0 | 52.0 | 58.0 |
| Ducts | 71.0 | 54.0 | 73.0 | 63.0 | 65.5 | 69.0 |
| Esophagus | 68.0 | 65.0 | | 62.0 | 68.0 | 67.0 |
| Larynx | 68.0 | 69.0 | | | | 68.0 |
| Multiple Myeloma | 72.0 | 68.0 | | 65.0 | 69.0 | 71.0 |
| Hodgkin's Lymphoma | 65.0 | | | | | 65.0 |
| All Other Sites | 72.0 | 64.0 | 69.0 | 68.5 | 62.0 | 71.0 |
| Total | 71.0 | 67.0 | 69.5 | 66.0 | 66.0 | 71.0 |

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE <u>HIGHLIGHTS</u>

- Thyroid Gland Cancer had the highest one-year survival rate of all types of cancer in Nevada from 2000 to 2004 with a rate of 98.6%. This was followed by Prostate, Breast, Hodgkin's Lymphoma, and Skin Cancers, which had one-year survival rates of 96.6%, 96.4%, 96.4%, and 96.2%, respectively.
- Pancreatic Cancer had the lowest one-year survival rate of all types of cancer in Nevada from 2000 to 2004 with a rate of 34.6%. This was followed by Liver and Intrahepatic Bile Ducts, Esophageal, Lung and Bronchus, and Stomach Cancers, which had one-year survival rates of 42.0%, 51.6%, 52.9%, and 59.9%, respectively.
- The five types of cancer with the highest five-year survival rates in Nevada from 2000 to 2004 were Thyroid Gland (97.7%), Hodgkin's Lymphoma (92.6%), Prostate (92.0%), Skin (90.1%), and Breast (88.9%) Cancers.
- The five types of cancer with the lowest five-year survival rates in Nevada from 2000 to 2004 were Pancreatic (23.4%), Liver and Intrahepatic Bile Ducts (30.1%), Esophageal (33.8%), Lung and Bronchus (37.1%), and Stomach (46.9%) Cancers.








Figure 21. Ten Lowest One-Year Survival Rates by Type of Cancer, Nevada Residents, 2000-2004








Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 2000-2004




Table 18. One-Year, Five-Year and Median Survival Rates by Type of
Cancer, Nevada Residents, 2000-2004

| Type of Cancer | 1-Year | 5-Year | Median Survival (Years) |
|--|--------|--------|----------------------------|
| Lung and Bronchus | 52.9% | 37.1% | 1.31 |
| Colorectal | 84.7% | 67.5% | > 5 YEARS |
| Breast | 96.4% | 88.9% | > 5 YEARS |
| Prostate | 96.6% | 92.0% | > 5 YEARS |
| Pancreas | 34.6% | 23.4% | 0.76 |
| Non-Hodgkin's Lymphoma | 85.6% | 73.3% | > 5 YEARS |
| Leukemia | 87.1% | 77.3% | > 5 YEARS |
| Liver and Intrahepatic Bile Ducts | 42.0% | 30.1% | 0.86 |
| Urinary Bladder | 92.2% | 81.3% | > 5 YEARS |
| Esophagus | 51.6% | 33.8% | 1.15 |
| Ovary | 76.4% | 54.5% | > 5 YEARS |
| Stomach | 59.9% | 46.9% | 3.19 |
| Kidney and Renal Pelvis | 82.3% | 71.1% | > 5 YEARS |
| Brain and Other Central Nervous System | 63.4% | 49.4% | 3.60 |
| Skin | 96.2% | 90.1% | > 5 YEARS |
| Multiple Myeloma | 87.0% | 67.5% | > 5 YEARS |
| Lip, Oral Cavity and Pharynx | 84.6% | 70.3% | > 5 YEARS |
| Larynx | 85.5% | 76.0% | > 5 YEARS |
| Cervix Uteri | 89.8% | 79.8% | > 5 YEARS |
| Corpus Uteri & Uterus NOS | 94.8% | 88.3% | > 5 YEARS |
| Hodgkin's Lymphoma | 96.4% | 92.6% | > 5 YEARS |
| Thyroid Gland | 98.6% | 97.7% | > 5 YEARS |
| All Other Sites | 71.4% | 61.5% | > 5 YEARS |
| Total | 82.3% | 71.9% | > 5 YEARS |

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 19. One-, Five-Year and Median Survival Rates by Type of Cancer,
Nevada Residents (2000-2004) and SEER-17 (2000-2004)

| Type of Capacr | 1-1 | fear | 5-Ye | ear | Median Survival | | |
|--|--------|-------------|--------|-------|-----------------|-----------|--|
| Type of Cancer | Nevada | SEER | Nevada | SEER | Nevada | SEER | |
| Lung and Bronchus | 52.9% | 43.1% | 37.1% | 16.0% | 1.31 | 88.0% | |
| Colorectal | 84.7% | 83.4% | 67.5% | 0.62 | > 5 YEARS | > 5 YEARS | |
| Breast | 96.4% | 96.8% | 88.9% | 0.86 | > 5 YEARS | > 5 YEARS | |
| Prostate | 96.6% | 98.1% | 92.0% | 0.91 | > 5 YEARS | > 5 YEARS | |
| Pancreas | 34.6% | 25.4% | 23.4% | 0.05 | 0.76 | 0.67 | |
| Non-Hodgkin's Lymphoma | 85.6% | 81.3% | 73.3% | 0.66 | > 5 YEARS | > 5 YEARS | |
| Leukemia | 87.1% | 70.1% | 77.3% | 0.51 | > 5 YEARS | > 5 YEARS | |
| Liver and Intrahepatic Bile Ducts | 42.0% | 38.3% | 30.1% | 0.16 | 0.86 | 0.81 | |
| Urinary Bladder | 92.2% | 90.4% | 81.3% | 0.77 | > 5 YEARS | > 5 YEARS | |
| Esophagus | 51.6% | 47.0% | 33.8% | 0.17 | 1.15 | 0.94 | |
| Ovary | 76.4% | 74.7% | 54.5% | 0.42 | > 5 YEARS | 3.50 | |
| Stomach | 59.9% | 51.5% | 46.9% | 0.25 | 3.19 | 1.10 | |
| Kidney and Renal Pelvis | 82.3% | 81.5% | 71.1% | 0.66 | > 5 YEARS | > 5 YEARS | |
| Brain and Other Central Nervous System | 63.4% | 61.1% | 49.4% | 0.38 | 3.60 | 1.75 | |
| Skin | 96.2% | 96.5% | 90.1% | 0.87 | > 5 YEARS | > 5 YEARS | |
| Multiple Myeloma | 87.0% | 75.9% | 67.5% | 0.39 | > 5 YEARS | 3.36 | |
| Lip, Oral Cavity and Pharynx | 84.6% | 84.1% | 70.3% | 0.62 | > 5 YEARS | > 5 YEARS | |
| Larynx | 85.5% | 87.1% | 76.0% | 0.64 | > 5 YEARS | > 5 YEARS | |
| Cervix Uteri | 89.8% | 88.6% | 79.8% | 0.72 | > 5 YEARS | > 5 YEARS | |
| Corpus Uteri & Uterus NOS | 94.8% | 92.2% | 88.3% | 0.80 | > 5 YEARS | > 5 YEARS | |
| Hodgkin's Lymphoma | 96.4% | 93.9% | 92.6% | 0.86 | > 5 YEARS | > 5 YEARS | |
| Thyroid Gland | 98.6% | 97.6% | 97.7% | 0.95 | > 5 YEARS | > 5 YEARS | |
| All Other Sites | 71.4% | 64.6% | 61.5% | 0.48 | > 5 YEARS | 3.82 | |
| Total | 82.3% | 79.0% | 71.9% | 0.63 | > 5 YEARS | > 5 YEARS | |

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 20. One- and Five-Year Survival Rates by Type of Cancer and Gender,Nevada Residents, 2000-2004

| | Gender | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--|--|
| Type of Cancer | Tot | al | Ма | le | Fem | ale | | |
| | 1-Year | 5-Year | 1-Year | 5-Year | 1-Year | 5-Year | | |
| Lung and Bronchus | 52.9% | 37.1% | 51.0% | 34.9% | 55.0% | 39.4% | | |
| Colorectal | 84.7% | 67.5% | 85.3% | 66.4% | 84.1% | 68.7% | | |
| Breast | 96.4% | 88.9% | 95.0% | 91.5% | 96.5% | 88.9% | | |
| Prostate | 96.6% | 92.0% | 96.6% | 92.0% | | | | |
| Pancreas | 34.6% | 23.4% | 34.7% | 24.1% | 34.5% | 22.5% | | |
| Non-Hodgkin's Lymphoma | 85.6% | 73.3% | 84.9% | 71.1% | 86.5% | 75.9% | | |
| Leukemia | 87.1% | 77.3% | 86.0% | 76.3% | 88.6% | 79.6% | | |
| Liver and Intrahepatic Bile Ducts | 42.0% | 30.1% | 36.9% | 22.8% | 53.0% | 43.8% | | |
| Urinary Bladder | 92.2% | 81.3% | 93.0% | 82.0% | 89.7% | 79.1% | | |
| Esophagus | 51.6% | 33.8% | 50.8% | 32.0% | 54.1% | 39.0% | | |
| Ovary | 76.4% | 54.5% | | | 76.4% | 54.5% | | |
| Stomach | 59.9% | 46.9% | 59.3% | 44.6% | 60.8% | 51.7% | | |
| Kidney and Renal Pelvis | 82.3% | 71.1% | 81.5% | 70.9% | 83.6% | 71.2% | | |
| Brain and Other Central Nervous System | 63.4% | 49.4% | 61.9% | 47.9% | 65.4% | 51.4% | | |
| Skin | 96.2% | 90.1% | 95.3% | 89.2% | 97.7% | 91.7% | | |
| Multiple Myeloma | 87.0% | 67.5% | 90.0% | 65.2% | 83.3% | 75.6% | | |
| Lip, Oral Cavity and Pharynx | 84.6% | 70.3% | 84.0% | 70.3% | 86.2% | 70.6% | | |
| Larynx | 85.5% | 76.0% | 85.3% | 77.0% | 86.1% | 71.3% | | |
| Cervix Uteri | 89.8% | 79.8% | | | 89.8% | 79.8% | | |
| Corpus Uteri & Uterus NOS | 94.8% | 88.3% | | | 94.8% | 88.3% | | |
| Hodgkin's Lymphoma | 96.4% | 92.6% | 94.1% | 94.1% | 99.0% | 91.4% | | |
| Thyroid Gland | 98.6% | 97.7% | 97.0% | 93.9% | 99.0% | 98.8% | | |
| All Other Sites | 71.4% | 61.5% | 73.0% | 63.0% | 69.1% | 59.3% | | |
| Total | 82.3% | 71.9% | 81.4% | 71.0% | 83.4% | 73.0% | | |

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to national rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the nation. For more information on the calculation of survival rates, please refer to Technical Notes section.